

TPMT: azathioprine/6-mercaptopurine

1905/1906

ALL = acute lymphoblastic leukaemia, AZA = azathioprine, CI = 95% confidence interval, Cl_{or} = oral clearance, cyto-stat = cytostatic agent, IBD = inflammatory bowel disease, HR = hazard ratio, HR_{adj} = adjusted hazard ratio, IM = intermediate metaboliser (reduced TPMT enzyme activity; *1/variant), imm sup = immunosuppressant, 6-MMP = 6-methylmercaptopurine, 6-MP = 6-mercaptopurine, MR = metabolic ratio, NM = normal metaboliser (normal TPMT enzyme activity; *1/*1), NS = non-significant, OR = odds ratio, PM = poor metaboliser (absent or severely reduced TPMT enzyme activity; variant/variant), RBC = (relating to) red blood cells, S = significant, TDM = therapeutic drug monitoring, 6-TG = thioguanine, 6-TGN = 6-thioguanine nucleotide, the active metabolite of azathioprine/6-mercaptopurine, TPMT = thiopurine S-methyltransferase, UM = ultra-rapid metaboliser (increased TPMT enzyme activity, not genetically determined), XO = xanthine oxidase

Disclaimer: The Pharmacogenetics Working Group of the KNMP formulates the optimal recommendations for each phenotype group based on the available evidence. If this optimal recommendation cannot be followed due to practical restrictions, e.g. therapeutic drug monitoring or a lower dose is not available, the health care professional should consider the next best option.

Brief summary and justification of choices:

Azathioprine is converted in the body to mercaptopurine. TPMT converts mercaptopurine primarily to inactive metabolites. The enzyme therefore reduces the percentage of mercaptopurine that is converted to the active metabolite. Genetic variations in TPMT lead to decreased enzyme activity, which results in an increased percentage of azathioprine and mercaptopurine that is converted to the active metabolite. Therapeutic and toxic concentrations of the active metabolite are therefore reached at lower doses.

All 5 meta-analyses and 11 of the 19 studies included in the risk analysis and investigating an association between adverse events and genetically reduced TPMT enzyme activity in patients using ≥ 1.5 mg/kg azathioprine or ≥ 0.75 mg/kg mercaptopurine per day confirm that patients with genetically reduced TPMT enzyme activity (intermediate metabolisers (IM) and poor metabolisers (PM)) have an increased risk for leukopenia and/or dose reduction due to adverse events like leukopenia (Dong 2010, Higgs 2010, Booth 2011, van Genne 2019, Jena 2021, Relling 1999, Evans 2001, Black 1998, Pandya 2002, Ansari 2002, Fabre 2004, Zelinkova 2006, Sheffield 2009, Lennard Br J Haematol 2015;169:228-40, Liu 2017, Dickson 2022). In addition, the only study investigating genotype-guided treatment with IM starting on 50% of the normal dose showed genotype-guided dosing to reduce leukopenia in IM (Coenen 2015).

Results of studies investigating an association between effectiveness and genetically reduced TPMT enzyme activity were contradictory, so there is no evidence that the increased risk in leukopenia is compensated for by a better effectiveness of treatment (Fabre 2004, Stanulla 2005, Gardiner 2008, Levinsen 2014, Lennard Br J Haematol 2015;169:228-40, Lennard Br J Haematol 2015;170:550-8, Dreisig 2021, and Nielsen 2021).

This is why the KNMP Pharmacogenetics Working Group decided that this concerns a gene-drug interaction and that action is required, namely to reduce the dose (yes/yes-interactions).

You can find a detailed overview of the observed clinical and kinetic effects per phenotype in the background information text of the gene-drug interactions in the KNMP Kennisbank. You might also have access to this background information text via your pharmacy or physician electronic decision support system.

Substantiation of the (dose) recommendation for each phenotype is provided below.

Justification of the (dose) recommendation per phenotype

If possible, doses are corrected for concentrations of the active metabolite (6-TGN). In the case of IM, doses are only included in the calculation if correction for 6-TGN concentration was possible, or if the study found no difference between NM and IM in the frequency of adverse events. All doses have been included for PM, because there was insufficient information available.

PM: Particularly in the case of PM, there is a clear link between the lower TPMT activity and the increased risk of adverse events. Patients with the PM phenotype are virtually always intolerant to the normal dose of azathioprine or 6-mercaptopurine. Out of the 45 PM cases in the literature, only 1 was able to tolerate the normal dose (Andersen 1998, McLeod 1999, Relling 1999, Evans 2001, Ansari 2002, Geary 2003, Kaskas 2003, Schaeffeler 2003, Gilissen 2004, Kurzawski Ther Drug Monit 2005, Kurzawski Transpl Int 2005, Stanulla 2005, Gardiner 2006, Zelinkova 2006, Newman 2011, Kim 2012, Lee 2013, Belen 2014, Demlova 2014, Kim 2014, Coenen 2015, Lennard Br J Haematol 2015;169:228-40, Lennard Br J Haematol 2015;170:550-8, Liu 2017). The dose adjustment calculated based on data from the literature is a reduction to 2.2%-124% of the normal dose (weighted mean 13.5%, median 10.5%) (n = 37). If the tolerant PM is excluded, then the calculated dose

adjustment is a reduction to 2.2%-15.5% of the normal dose (weighted mean 10.4%, median 10.3%) (n = 36). This was translated to 10% to be more achievable in clinical practice.

Adjustment of the initial dose should be guided by toxicity and effectiveness.

IM: Contradictory results were found regarding the influence of the IM phenotype on the effectiveness of the therapy. In addition, when used as an oncolytic drug, there are reports of an increase in secondary malignant tumours in IM (see Comments/Dose recommendations in reviews/articles at the end of this risk analysis and Levinson 2014). Lennard found a non-significantly increased effectiveness for *1/*3A and a decreased effectiveness for *1/*3C in a study involving 709 children, but found no influence of the IM phenotype or any of the IM genotypes on effectiveness in a study involving 2387 patients, aged 1-25 years, and a more effective treatment protocol (Lennard Br J Haematol 2015;169: 228-40, and Lennard Br J Haematol 2015;170:550-8). Gardiner 2008 found no difference in clinical outcome between IM and NM in a group of 52 patients with inflammatory bowel disease. Fabre 2004 found no difference in the percentage of patients with at least one acute rejection episode between IM and NM in a group of 172 kidney transplant patients. Dreisig 2021 found no influence of the IM phenotype on the percentage of patients with remaining leukaemia cells after consolidation therapy in a study involving 942 patients aged 1-45 years, despite a 1.5 fold higher thioguanine incorporation into DNA in IM compared to NM. However, in a study with 810 patients, Stanulla 2005 found a lower frequency of remaining leukaemia cells above the detection limit for IM compared to NM, but not for PM on 10% of the normal 6-mercaptopurine dose compared to NM. Nielsen 2021 found no difference in 5-year cumulative incidence of relapse in 918 children between IM at 67% of the normal initial dose and NM at the normal initial dose, despite a 1.5 fold higher thioguanine incorporation into DNA in IM compared to NM. Levinson 2014 found no difference in effectiveness in 674 children and no difference in new tumours between IM at 67% of the normal initial dose and NM at the normal initial dose. Therefore, there are not enough indications to support an increased effectiveness for IM at the normal dose and a decrease in effectiveness with dose reduction. However, for oncolytics, toxicity and efficacy are strongly coupled, and it is unknown whether starting with a dose reduction based on genotype results in the same efficacy as reducing the dose based on toxicity.

The dose adjustment calculated based on data from the literature is a reduction to 32%-100% of the normal dose (weighted mean 73%, median 46%) (n = 103). Due to the severity of the adverse event myelosuppression and the large difference between the median and weighted mean, the KNMP Pharmacogenetics Working Group decided to use the median of the calculated dose adjustment as the initial dose instead of the weighted mean. This ensures that the adverse event is avoided as far as possible, whilst dose adjustment based on toxicity and effectiveness prevents underdosing. This median was translated to 50% to be more achievable in clinical practice.

Adjustment of the initial dose should be guided by toxicity and effectiveness.

As low doses (to 1.5 mg/kg azathioprine or 0.75 mg/kg mercaptopurine per day) do not result in a significant increase in the percentage of patients with adverse events in the case of IM (Langley 2002, Jun 2005, Hindorf 2010, Eriksen 2017, Fan 2019, and Miao 2021), dose adjustment is not required for doses up to this strength. Because for oncology indications, it is unknown whether starting with a dose reduction based on the IM phenotype results in the same efficacy as reducing the dose based on toxicity, the KNMP Pharmacogenetics Working Group recommends to either start with 50% of the normal mercaptopurine dose or to start with the normal dose and reduce to 50% when adverse events necessitate a dose reduction. In determining the starting dose, next to the IM phenotype, the physician needs to take into account the comorbidity (e.g. the sensitivity for infections), the patient wishes (taking into account the above mentioned uncertainty) and the estimation of the aggression of the tumour (e.g. based on tumour genetics). When treating patients with the normal dose according to acute lymphoblastic leukaemia guidelines, IM patients require a mercaptopurine dose reduction more often than NM patients (final median dose 86% for NM, 59% for *1/*3A, 63% for *1/*2, and 72% for *1/*3C (Liu 2017)). However, dose reduction is also frequently required for NM patients and there is a large overlap in the final dose range of the two phenotypes (Liu 2017).

Recommendation concerning pre-emptive genotyping, including justification of choices:

The Dutch Pharmacogenetics Working Group considers genotyping before starting azathioprine or 6-mercaptopurine to be essential for drug safety. Genotyping must be performed before drug therapy has been initiated to guide drug and dose selection.

The clinical implication of the gene-drug interaction scores 7 out of the maximum of 10 points (with pre-emptive genotyping considered to be essential for scores ranging from 6 to 10 points):

Cases of unsuspected, possibly life-threatening myelosuppression have been observed in PM (code F corresponding to grade 5). The SmPC of azathioprine from the USA also reports fatal cases. This results in the maximum of 2 points for the first criterion of the clinical implication score, the clinical effect associated with the gene-drug interaction (2 points for CTCAE grade 5).

The increased risk for serious toxicity (code E corresponding to grade 4) has been shown in 3 studies and 1 systematic review (Lennard Br J Haematol 2015;169:228-40, Evans 2001, Relling 1999, and Higgs 2010). This results in the maximum score of 3 points for the second criterion of the clinical implication score, the level of evidence supporting the associated clinical effect grade ≥ 3 (3 points for three or more publications with level of evidence

score ≥ 3).

The study of Coenen 2015 indicates the percentage of IM+PM with leukopenia grade ≥ 2 to decrease from 22.9% to 2.6% by introducing genotype-guided dosing. However, it does not state how many of these patients have leukopenia grade ≥ 3 . Because almost all PM develop severe leukopenia and intolerance on normal thiopurine doses, the prevalence of PM was used for estimation of the number needed to genotype to prevent an adverse event grade ≥ 3 instead. The frequencies of the *2-, *3A-, *3B- and *3C-alleles in the Netherlands are 0.4, 3.5, 0.4 and 0.8% respectively, corresponding to a PM frequency of 0.26%. This would amount to a number needed to genotype to find one PM, and thus one patient developing an adverse event grade ≥ 3 on normal therapy, of 384. The calculated number needed to genotype of 384 results in 1 out of the maximum of 3 points (1 point for $100 < \text{NNG} \leq 1000$).

The Dutch Summaries of Product Characteristics (SmPCs) indicate that PM have an increased risk for myelosuppression at conventional doses of thiopurine therapy. This results in 1 out of the maximum of 2 points for the fourth and last criterion of the clinical implication score, the pharmacogenetics information in the SmPC (1 point for at least one genotype/phenotype mentioned in the SmPC, but not mentioned as a contra-indication and no recommendation to genotype).

Despite genotyping before starting azathioprine or 6-mercaptopurine scoring as essential for drug safety, results from 12 cost-effectiveness analyses are inconclusive and tend to point to a lack of cost-effectiveness (Zarca 2019 and Plumpton 2016). However, the 3 most recent cost-effectiveness analyses suggest cost-effectiveness (van der Wouden 2022, Zeng 2021 and Sluiter 2019).

The table below uses the KNMP nomenclature for NM, PM and IM. As a result, the definitions of NM, PM and IM in the table below can differ from the definitions used by the authors in the article.

Before 2011, articles with the indication immune suppression were included first, followed by articles with both the indications immune suppression and cytostatic therapy, and ending with articles with the indication cytostatic therapy. Within each group, articles were included in order of publication date (most recent first). From 2011, articles were included in order of publication date only.

Source	Code	Effect	Comments																		
ref. 1, imm sup Sheu HS et al. Thiopurine S-methyltransferase polymorphisms predict hepatotoxicity in azathioprine-treated patients with autoimmune diseases. J Pers Med 2022;12:1399. PMID: 36143183 Free PMC article.	3	50 azathioprine-treated non-NM patients were compared to 1000 azathioprine-treated NM patients. The non-NM and NM patients were matched by age and gender. Hepatitis B infection was more prevalent in non-NM than in NM (12.0% versus 3.6% of patients) The mean azathioprine dose was 39.4 mg/day. Treatment was started with a low azathioprine dose followed by increasing the dose at a slow pace. Leukopenia was defined as a white blood cell count below $4 \times 10^9/\text{L}$. Hepatotoxicity was defined as an alanine transaminase level $\geq 150 \text{ U/L}$, which corresponds to more than 3 times the upper limit of normal. Relevant co-medication was not excluded. Cox regression analysis adjusted for age, gender, azathioprine dose, methotrexate comedication and hepatitis B infection. Genotyping: - 1000x NM - 49x IM - 1x PM Results: <table><tr><th colspan="3">Results for IM+PM compared to NM:</th></tr><tr><td></td><td></td><td>value for NM</td></tr><tr><td>% of patients with leukopenia</td><td>NS</td><td>63.3%</td></tr><tr><td>lowest white blood cell count</td><td>NS</td><td>4200 U/L</td></tr><tr><td>time to onset of leukopenia</td><td>NS</td><td>1597 days</td></tr><tr><td>% of patients</td><td>NS</td><td>15.0%</td></tr></table>	Results for IM+PM compared to NM:					value for NM	% of patients with leukopenia	NS	63.3%	lowest white blood cell count	NS	4200 U/L	time to onset of leukopenia	NS	1597 days	% of patients	NS	15.0%	Authors' conclusion: 'A TPMT non-NM genotype was associated with the occurrence of hepatotoxicity following azathioprine therapy. Preemptive testing helps individualize azathioprine therapy by minimizing the risk of hepatotoxicity.'
Results for IM+PM compared to NM:																					
		value for NM																			
% of patients with leukopenia	NS	63.3%																			
lowest white blood cell count	NS	4200 U/L																			
time to onset of leukopenia	NS	1597 days																			
% of patients	NS	15.0%																			

ref. 1, continuation	IM+PM: C	with hepatotoxi- city												
		highest alanine transaminase level	NS	39 U/L										
		time to onset of hepatotoxicity	x 0.28 (S)	2396 days										
			Cox regression analysis showed IM+PM to be an independent risk factor for hepatotoxicity: HR = 3.85 (95% CI: 1.83- 8.10) (S)											
			The cumulative incidence of hepatotoxicity was higher in the first three years for IM+PM than for NM (S). For IM+PM, the 1-year cumulative incidence rate was 8.5% and the 2-year and 3-year cumulative incidence rates were both 18.6%, whereas the 3-year cumulative incidence rate for NM was approximately 5.8%.											
azathioprine dose	NS	39.6 mg/day												
		NOTE: The authors indicated that the lack of adjustment for the NUDT15 genotype is a limitation of this study. NUDT15 was reported to be associated with more frequent adverse events than TPMT in the Asian population, which is due to the high prevalence of NUDT15 gene variants in Asians.												
		NOTE: Genotyping was for the gene variant present in both *3C and *3A. This is the most important gene variant in this Taiwanese population.												
ref. 2, imm sup Casajús A et al. Genotype-guided prescription of azathioprine redu- ces the incidence of adverse drug reac- tions in TPMT inter- mediate metaboli- zers to a similar incidence as normal metabolizers. Adv Ther 2022;39:1743-53. PMID: 35192152.	3 Genotype- guided the- rapy with IM on 73% of the normal initial dose: IM: C	109 patients received genotype-guided azathioprine treat- ment (the initial dose for IM was 73% of that for NM). The initial dose was subtherapeutic for both NM and IM. The recommended dose is 2.5 mg/kg per day (around 175 mg/day). Leukopenia was defined as a white blood cell count below 2.5x10 ⁹ /L. Hepatotoxicity was clinically defined. Co-medication with other immunosuppressive agents was excluded with the exception of corticosteroids (73.4% of patients) and salicylates, but other relevant co-medication was not excluded. In addition, a control group receiving not- genotype-guided therapy was lacking. Genotyping: - 101x NM - 8x IM Results: <table><tr><th colspan="3">Results for IM compared to NM:</th></tr><tr><td></td><td></td><td>value for NM</td></tr><tr><td>% of patients with a treatment duration ≥ 6 months</td><td>x 0 (S) Of the 4 IM with a known reason for treatment dis- continuation, this was due</td><td>62.4%</td></tr></table>			Results for IM compared to NM:					value for NM	% of patients with a treatment duration ≥ 6 months	x 0 (S) Of the 4 IM with a known reason for treatment dis- continuation, this was due	62.4%	Authors' conclu- sion: 'TPMT genotyping before azathio- prine prescription reduces adverse drug reaction inci- dence in IMs to a similar level as NMs in the Spa- nish population. However, it is important to note no IMs completed 6 months of treat- ment, suggesting that there may be some differences in drug tolerability according to phe- notype.'
Results for IM compared to NM:														
		value for NM												
% of patients with a treatment duration ≥ 6 months	x 0 (S) Of the 4 IM with a known reason for treatment dis- continuation, this was due	62.4%												

ref. 2, continuation			to adverse events in 3, while 1 died of an unrelated cause.		
		% of patients with adverse events	NS		27.8%
		% of patients with leukopenia	NS		4.6%
		% of patients with blood disorders (including leukopenia)	NS		8.9%
		% of patients with hepatotoxicity	NS		9.9%
		% of patients with gastric intolerance	NS		8.9%
		initial azathioprine dose	NS		103.2 mg/day
		final azathioprine dose	x 0.65 (S)		120.3 mg/day
		% of patients requiring dose adjustment during treatment	x 0.25 (S)		50.5%
	NOTE: Genotyping was for *2, *3A, *3B and *3C. These are the most important gene variants in this Spanish population.				
ref. 3, imm sup Dickson AL et al. TPMT and NUDT15 variants predict discontinuation of azathioprine for myelotoxicity in patients with inflammatory disease: real-world clinical results. Clin Pharmacol Ther 2022;111:263-71. PMID: 34582038.	3	1403 patients were treated with azathioprine. Median follow-up was 19.1 months. The mean initial dose was 80 mg/day. 51% of patients was tested for TPMT (either genetically or by enzyme activity) before start of azathioprine. The proportion of patients taking azathioprine for inflammatory bowel disease was greater in patients without than in patients with a TPMT or NUDT15 gene variant 35.0% versus 22.7%. Relevant co-medication was not excluded. In addition, genotyping was only for the gene variant in *3C and *3A. Genotypes for TPMT *2 and *3B and for NUDT15 were imputed. Hazard ratios were adjusted for reported race, age at initial dose, sex, primary indication, and initial daily dose of azathioprine. Genotyping (*3C and *3A) and imputation (*2, *3B and NUDT15 *2 and *3): - 1303x NM (including 10x NUDT15 IM) - 96x IM - 4x PM Results: Results for (TPMT IM+PM + NUDT15 IM) compared to NM for both TPMT and NUDT15:			Authors' conclusion: 'TPMT and NUDT-15 metabolizer status predicts discontinuation due to myelotoxicity for patients taking azathioprine for inflammatory conditions.'
				value for NM	
	% of patients discontinuing azathioprine due to myelotoxicity	HR _{adj} = 2.67 (95% CI: 1.44-4.94) (S)	Results were similar when comparing TPMT IM+PM and TPMT NM: HR _{adj} = 2.74 (95% CI: 1.45-5.18) (S) Results remained signifi-	4.4%	

ref. 3, continuation	Genotype-guided therapy with IM+PM on 77% of the normal initial dose: IM+PM: C			cant after inclusion of adjustment for weight-corrected initial dose: HR _{adj} = 2.12 (95% CI: 1.10-4.08) (S)			
				Results were significant in the subgroup of White patients (n = 1225): HR _{adj} = 2.34 (95% CI: 1.10-5.00) (S) and there was a trend for an increased risk in the subgroup of Black patients (n = 149): p = 0.081 (NS). The sample size was too small to draw any conclusions for other ethnicities.			
				Results were significant in both the patients with pretherapeutic TPMT testing (n = 713): HR _{adj} = 2.49 (95% CI: 1.06-5.83) (S) and the patients without pretherapeutic TPMT testing (n = 690): HR _{adj} = 2.68 (95% CI: 1.08-6.66) (S). Pretherapeutic TPMT testing did not decrease the risk for either IM+PM or for NM.			
		initial azathioprine dose	all	x 0.83 (S)	81.1 mg/day		
			prior TPMT testing	x 0.77 (S)	90 mg/day		
			no prior TPMT testing	x 0.89 (NS)	72 mg/day		
		final azathioprine dose	prior TPMT testing	x 0.79 (NS, significance not determined)	115 mg/day		
			no prior TPMT testing	x 0.89 (NS, significance not determined)	99 mg/day		
		NOTE: Genotyping was for the gene variant in *3C and *3A. Imputation was for the gene variant in *3B and *3A, for *2, and for the gene variant in NUCT15 *3 and *2. These are the most important gene variants in this population from the USA.					
		ref. 4, cytostat	3	918 paediatric patients with acute lymphoblastic leukaemia received genotype-guided maintenance therapy including 6-mercaptopurine and methotrexate until 2.5 years after diagnosis. 6-mercaptopurine starting dose was 75 mg/m ² for NM and 50 mg/m ² (67%) for IM. The dose was titrated based on a target white blood cell count of 1.5-3.0x10 ⁹ /L Only patients with low or intermediate risk acute lymphoblastic leukaemia and with at least one measurement of thiopurine incorporation into DNA were included. The estimated median follow-up			Authors' conclusion: 'TPMT heterozygosity is not associated with relapse-specific hazard in non-high risk NOPHO ALL2008 patients, and 6-mercaptopurine

a NOPHO ALL2008 sub-study. Cancer Chemother Pharmacol 2021;88:271-9. PMID: 33928426. ref. 4, continuation	Genotype guided therapy with IM on 67% of the normal initial dose: IM: AA	time was 8.0 years (interquartile range 0.4-11.8 years). The study protocol urged that TPMT enzyme activity (TPMT phenotype) was assessed repeatedly, first at diagnosis and then approximately every 6 months during maintenance therapy. TPMT enzyme activity was not reported to the clinics. Relevant co-medication was not excluded, but comorbidities were. The relapse hazard ratio was adjusted for sex, age, and white blood cell count at diagnosis. Genotyping: - 903x NM - 78x IM Results: <table><tr><th colspan="3">Results for IM compared to NM:</th></tr><tr><th></th><th></th><th>value for NM</th></tr><tr><td>5-year cumulative incidence of relapse</td><td>NS</td><td>6.0%</td></tr><tr><td>median thioguanine incorporated in DNA (measured in maintenance II, i.e. at least 57 weeks after diagnosis, n = 548)</td><td>x 1.54 (S)</td><td>492.7 fmol/μg DNA</td></tr><tr><td>TPMT activity during maintenance therapy in patients remaining in remission during follow-up (n = 752)</td><td>x 0.58 (S)</td><td>16.6 U/ml erythrocytes</td></tr></table> NOTE: TPMT activity during maintenance therapy was not associated with relapse-specific hazard rate in this study. NOTE: Genotyping was at least for *3A, *3B and *3C. These are the most important gene variants in this population from Denmark, Estonia, Finland, Iceland, Lithuania, Norway, and Sweden.	Results for IM compared to NM:					value for NM	5-year cumulative incidence of relapse	NS	6.0%	median thioguanine incorporated in DNA (measured in maintenance II, i.e. at least 57 weeks after diagnosis, n = 548)	x 1.54 (S)	492.7 fmol/μg DNA	TPMT activity during maintenance therapy in patients remaining in remission during follow-up (n = 752)	x 0.58 (S)	16.6 U/ml erythrocytes	dosage guidelines should not differ from those provided for TPMT wild-type patients.'
Results for IM compared to NM:																		
		value for NM																
5-year cumulative incidence of relapse	NS	6.0%																
median thioguanine incorporated in DNA (measured in maintenance II, i.e. at least 57 weeks after diagnosis, n = 548)	x 1.54 (S)	492.7 fmol/μg DNA																
TPMT activity during maintenance therapy in patients remaining in remission during follow-up (n = 752)	x 0.58 (S)	16.6 U/ml erythrocytes																
ref. 5, imm sup Miao Q et al. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in Southwest China patients with autoimmune hepatitis. Sci Rep 2021;11:7984. PMID: 33846471.	3	113 patients with autoimmune hepatitis received azathioprine maintenance therapy for more than 12 weeks. The initial azathioprine dose was usually 1-1.5 mg/kg per day. Patients who developed myelosuppression during treatment with azathioprine had their dose reduced first, usually to 50% of the initial dose. If myelosuppression persisted, azathioprine was discontinued. Complete blood cell count was performed every week during the first month and every two weeks during the second and third month. Myelosuppression was defined as a white blood cell count of < 4x10⁹/L, platelet count of < 100x10⁹/L, or neutrophil count of < 2x10⁹/L. Azathioprine-induced myelosuppression was considered when other diseases that cause myelosuppression were excluded. Co-medication that may lead to myelosuppression was excluded, but co-medication affecting TPMT was not. Odds ratios were determined using logistic regression analysis.	Authors' conclusion: 'The NUDT15 variant was associated with leukopenia and neutropenia; however, no significant association with myelosuppression was observed for TPMT*3C and ITPA variants.'															

ref. 5, continuation		sis. Genotyping: - 111x NM - 2x IM Results: <table><tr><th colspan="3">Results for IM compared to NM:</th></tr><tr><th></th><th></th><th>value for NM</th></tr><tr><td>% of patients with myelo-suppression</td><td>NS</td><td>36%</td></tr><tr><td>% of patients with leukopenia</td><td>NS</td><td>13.5%</td></tr><tr><td>% of patients with thrombo-cytopenia</td><td>NS</td><td>30.6%</td></tr><tr><td>% of patients with neutropenia</td><td>NS</td><td>9.0%</td></tr><tr><td>median 6-TGN level (in pmol/ 8x10⁸ RBC)</td><td>NS</td><td>123.3</td></tr><tr><td>median dose- and weight-adjusted 6-TGN level (in pmol/ 8x10⁸ RBC per mg/kg per day)</td><td>x 4.64 (NS)</td><td>0.036</td></tr></table> Note: the azathioprine dose in the 2 IM was less than 1 mg/kg. The authors indicate that the lack of significance observed for the TPMT variant in the study may be due to its low prevalence and the small sample size of the study. NOTE: The polymorphism that is present in both NUDT15 *2 and *3 was significantly associated with myelosuppression, leukopenia, and neutropenia in this patient group, suggesting the lack of an association for TPMT *3C to be indeed due to the small number of patients with a variant allele. However, the outcomes concerned mild myelosuppression, leukopenia, thrombocytopenia and neutropenia (severity code B), regardless of the presence of absence of symptoms. NOTE: Genotyping was for *3C. This is the most important gene variant in this Chinese population.	Results for IM compared to NM:					value for NM	% of patients with myelo-suppression	NS	36%	% of patients with leukopenia	NS	13.5%	% of patients with thrombo-cytopenia	NS	30.6%	% of patients with neutropenia	NS	9.0%	median 6-TGN level (in pmol/ 8x10 ⁸ RBC)	NS	123.3	median dose- and weight-adjusted 6-TGN level (in pmol/ 8x10 ⁸ RBC per mg/kg per day)	x 4.64 (NS)	0.036	
Results for IM compared to NM:																											
		value for NM																									
% of patients with myelo-suppression	NS	36%																									
% of patients with leukopenia	NS	13.5%																									
% of patients with thrombo-cytopenia	NS	30.6%																									
% of patients with neutropenia	NS	9.0%																									
median 6-TGN level (in pmol/ 8x10 ⁸ RBC)	NS	123.3																									
median dose- and weight-adjusted 6-TGN level (in pmol/ 8x10 ⁸ RBC per mg/kg per day)	x 4.64 (NS)	0.036																									
ref. 6, imm sup/ cytostat Jena A et al. Prevalence of polymorphisms in thio-purine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis. Expert Rev Clin Pharmacol 2021;14:491-501. PMID: 33682590.	3	Meta-analysis of 10 South Asian studies into adverse events caused by azathioprine or mercaptopurine in a total of 1,040 patients with inflammatory diseases, auto-immune diseases or acute lymphoblastic leukaemia (including 287 IM+PM). 9 of the included studies met all 9 study quality checks on the Joanna Briggs Institute critical appraisal checklist. For the 10th study, it was unclear whether 2 of the checks, both concerning the measurement of leukopenia, were met. For 1 of the included studies, only a conference abstract was available. Adverse events were defined as a combination of adverse events as reported in each study (leukopenia, myelosuppression, febrile neutropenia, drug discontinuation/reduction). None of the 10 studies in the meta-analysis were included in this risk analysis separately. None of the 10 studies in the meta-analysis were included in	Authors' conclusion: 'The odds ratio (OR) of adverse events with presence of TPMT polymorphisms was 3.65.'																								

ref. 6, continuation		in the meta-analyses of Van Gennep 2019, Booth 2011, Dong 2010, and Higgs 2010. The meta-analysis was performed with a prospectively chosen random-effects model, but prospective registration of the protocol was not mentioned. The search and selection strategy was transparent and data extraction was standardised. Quality of the included studies was judged with a less common checklist recommending against a score cut-off for quality assessment. Potential publication bias was assessed for the gene variant prevalence outcome only (24 studies), not for the adverse event outcome (10 studies). Results: <table><tr><th colspan="3">% of patients with adverse events compared to NM:</th></tr><tr><td></td><td></td><td>value for NM</td></tr><tr><td>IM+PM</td><td>OR = 3.65 (95% CI: 1.43-9.28) (S)</td><td>2.4%</td></tr><tr><td colspan="3">Heterogeneity between the studies was significant, but low.</td></tr></table>	% of patients with adverse events compared to NM:					value for NM	IM+PM	OR = 3.65 (95% CI: 1.43-9.28) (S)	2.4%	Heterogeneity between the studies was significant, but low.			
% of patients with adverse events compared to NM:															
		value for NM													
IM+PM	OR = 3.65 (95% CI: 1.43-9.28) (S)	2.4%													
Heterogeneity between the studies was significant, but low.															
ref. 7, cytostat Dreisig K et al. TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. Pediatr Hematol Oncol 2021;38:227-38. PMID: 33205673.	3	942 patients, aged 1-45 years, with acute lymphoblastic leukaemia received consolidation therapy including 6-mercaptopurine and methotrexate for 50 days. 6-mercaptopurine dose was 25 mg/m² per day. Methotrexate dose was 5 g/m² intravenously at day 7 and 28 of consolidation therapy. Data on minimal residual disease after consolidation therapy were available for 902 patients, data on treatment interruption for 382 patients, and data on DNA-incorporated thioguanine in 477 patients. Minimal residual disease (i.e. remaining leukaemia blasts in bone marrow) was measured before and after consolidation treatment. Patients with blast levels $\geq 10^{-4}$ were considered to have minimal residual disease. DNA-incorporated thioguanine was measured in the last 10 days of consolidation therapy. Relevant co-medication was not excluded. Logistic regression analysis of minimal residual disease adjusted for sex, central nervous system status, age at diagnosis, white blood cell count at diagnosis, DNA-index, plus the number of days without 6-mercaptopurine. Genotyping: - 861x NM - 81x IM Results: <table><tr><th colspan="3">Results for IM compared to NM:</th></tr><tr><td></td><td></td><td>value for NM</td></tr><tr><td>% of patients with minimal residual disease before consolidation therapy</td><td>NS in univariate and logistic regression analysis</td><td>46%</td></tr><tr><td>% of patients with minimal residual disease after consolidation therapy</td><td>NS in univariate and logistic regression analysis</td><td>10%</td></tr></table>	Results for IM compared to NM:					value for NM	% of patients with minimal residual disease before consolidation therapy	NS in univariate and logistic regression analysis	46%	% of patients with minimal residual disease after consolidation therapy	NS in univariate and logistic regression analysis	10%	Authors' conclusion: 'The levels of the cytotoxic DNA-incorporated thioguanine were significantly higher on day 70-79 in G460A/A719G TPMT heterozygous compared to TPMT wild type patients. In contrast, TPMT genotype did not associate with the end of consolidation minimal residual disease levels'
Results for IM compared to NM:															
		value for NM													
% of patients with minimal residual disease before consolidation therapy	NS in univariate and logistic regression analysis	46%													
% of patients with minimal residual disease after consolidation therapy	NS in univariate and logistic regression analysis	10%													

ref. 7, continuation	IM: A	% of patients with 6-mercaptopurine treatment interruptions	NS	69.6%									
		median number of days without 6-mercaptopurine treatment	NS	7 days									
		DNA-incorporated thioguanine at day 41-50 of consolidation therapy	x 1.54 (S)	149.7 fmol/ µg DNA									
		NOTE: Genotyping was for *3A, *3B and *3C. These are the most important gene variants in this population from Denmark, Estonia, Finland, Iceland, Lithuania, Norway, and Sweden.											
ref. 8, imm sup van Gennep S et al. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther 2019;50:484-506. PMID: 31342537.	3	Meta-analysis of 30 studies into azathioprine- or mercaptopurine-induced leukopenia and/or neutropenia in a total of 8404 patients with inflammatory bowel disease (including 561 IM+PM). The meta-analysis comparing IM to NM included 28 articles with a total of 5898 NM and 357 IM. The meta-analysis comparing PM to NM included 8 articles with a total of 1264 NM and 9 PM. Of the 30 studies included in the meta-analysis, 1 scored the maximum of 9 points on the Newcastle-Ottawa quality assessment scale, 2 scored 8 points, 8 scored 7 points, 7 scored 6 points, 9 scored 5 points, and 3 scored 4 points. Studies with a score below 6 were considered to have high risk of bias. This concerned 12 of the 30 studies in the meta-analysis for IM+PM, 12 of the 28 studies in the meta-analysis for IM, and 4 of the 8 studies in the meta-analysis for PM. Leukopenia and/or neutropenia was defined as a white blood cell count below 4.0x10⁹/L and/or a neutrophil count below 2x10⁹/L. 3 of the 30 studies in the meta-analysis were included in this risk analysis separately (Coenen 2015, Zelinkova 2006, and Gearry 2003). 7 of the 30 studies in the meta-analysis were included in the meta-analyses of Booth 2011 (Kim 2010, Kolorz 2009, Winter 2007, Zelinkova 2006, Derijks 2004, Hibi 2003, and Jojic 2003) and Higgs 2010 (Winter 2007, Hindorf 2006, Zelinkova 2006, Derijks 2004, Hibi 2003, Jojic 2003, and Schwab 2002), and 6 were included in the meta-analysis of Dong 2010 (Palmieri 2007, Winter 2007, Hindorf 2006, Zelinkova 2006, Derijks 2004, and Schwab 2002). The meta-analyses were performed with a prospectively chosen random-effects model, but prospective registration of the protocol was not mentioned. The search and selection strategy was transparent and data extraction was standardised. Potential publication bias was not assessed. Results: <table><tr><td colspan="3">% of patients with leukopenia and/or neutropenia compared to NM:</td></tr><tr><td>IM</td><td>OR = 3.56 (95% CI: 2.28-5.55) (S)</td><td rowspan="2">OR = 3.72 (95% CI: 2.42-5.72) (S)</td></tr><tr><td>PM</td><td>OR = 75.7 (95% CI: 22.7-252.4) (S)</td></tr></table>			% of patients with leukopenia and/or neutropenia compared to NM:			IM	OR = 3.56 (95% CI: 2.28-5.55) (S)	OR = 3.72 (95% CI: 2.42-5.72) (S)	PM	OR = 75.7 (95% CI: 22.7-252.4) (S)	Authors' conclusion: 'TPMT and NUDT-15 variants predict thiopurine-induced leukopenia. Potential preventive measures to reduce the risk of thiopurine-induced leukopenia include pre-treatment TPMT and NUDT-15 genotyping.'
% of patients with leukopenia and/or neutropenia compared to NM:													
IM	OR = 3.56 (95% CI: 2.28-5.55) (S)	OR = 3.72 (95% CI: 2.42-5.72) (S)											
PM	OR = 75.7 (95% CI: 22.7-252.4) (S)												
	IM C PM: C												

ref. 9, continuation		NUDT15 IM after achieving biochemical remission was 0.96 mg/kg per day, the authors conclude that safety and efficacy can be maintained in most NUDT15 IM at lower azathioprine doses of approximately 1 mg/kg per day. NOTE: The authors indicate that current guidelines, including the clinical practice guidelines for autoimmune hepatitis by the European Association for the Study of the Liver (EASL) and by the American Association for the Study of Liver Diseases (AASLD), recommend TPMT genotyping prior to initiation of azathioprine treatment (European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63:971-1004. PubMed PMID: 26341719; Manns MP et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213. PubMed PMID: 20513004). NOTE: Genotyping was for *3C. This is the most important gene variant in this Chinese population.	
ref. 10, cytostat, kinetics Choi R et al. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 2019 Mar 30 [Epub ahead of print]. PubMed PMID: 30927276.	3 		

ref. 13, continuation	PM: B	were increased to 4.8 times the upper limit of the therapeutic range (2353 pmol/8x10⁸ RBC). Azathioprine treatment was stopped. After 3 weeks, a mild thrombocytopenia (101x10⁹/L) was shown, which resolved spontaneously within 1 week. Genotyping showed the patient to be PM (*3A/*3C). - After 6.5 weeks azathioprine was restarted in a dose of 75 mg once weekly (corresponding to 0.15 mg/kg per day). 6-TGN levels increased from 0.66 times to 1.23 times the upper limit of the therapeutic range (321 to 605 pmol/8x10⁸ RBC) in 3 weeks. - After a reduction of the azathioprine dose to 50 mg once weekly (corresponding to 0.10 mg/kg per day, i.e. 4% of the normal dose), the 6-TGN levels remained between 500 and 600 pmol/8x10⁸ RBC without signs of myelotoxicity. After 11 weeks, leukocyte count showed a mild leukopenia (3.0-4.0x10⁹/L), which recovered within 5 weeks without intervention. Platelet count was normal (between 175 and 271x10⁹/L). The patient was in clinical remission on a maintenance dose of 50 mg azathioprine once weekly for almost 5 years at the time of reporting. NOTE: The authors indicate that pre-emptive TPMT testing is suggested by guidelines of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) (Turner D et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340-61. PubMed PMID: 22773060). Therefore, all patients with inflammatory bowel disease in their hospital currently undergo pre-emptive TPMT testing when thiopurine therapy is indicated.	Dose versus normal dose: PM: 4%
ref. 14, imm sup Coenen MJ et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology 2015;149:907-17. PubMed PMID: 26072396.	3	783 patients with inflammatory bowel disease were treated with azathioprine (64% of patients) or 6-mercaptopurine (36% of patients). Follow-up was for a period of 20 weeks. Genotype-guided treatment (n = 405) was compared to standard treatment (n = 378). Standard treatment was azathioprine 2-2.5 mg/kg/day or 6-mercaptopurine 1-1.5 mg/kg/day). In the genotype-guided group, NM received the normal thiopurine dose and IM 50% of the normal dose. PM were scheduled to receive 0-10% of the normal dose and the only PM in the study did not receive a thiopurine. 13% of patients in the standard treatment group and 15% of patients in the genotype-guided group did not receive the allocated intervention, mostly (for 84% and 90% respectively) due to a starting dose not according to the advice. Gastroenterologists were allowed to change the thiopurine dose or stop treatment when a side effect occurred. The guidelines were to consider a dose reduction by a leukocyte count ≤ 4x10⁹/L and a fast decrease of leukocyte count, to reduce the dose with 50% by a leukocyte count of ≤ 3x10⁹/L, and to stop treatment by a leukocyte count < 1x10⁹/L. Treatment re-challenge was at the discretion of the gastroenterologist. Two patients died due to infections, one IM who was started on a reduced thiopurine dose and one NM. Hematologic adverse events were defined as leukocyte count < 3.0x10⁹/L or platelet count < 100x10⁹/L. Disease activity was based on the Harvey-Bradshaw Index for Crohn's disease (n = 356) or the partial Mayo score for ulcerative colitis (n = 253). Remission was defined as a score on the Harvey-Bradshaw Index < 5 (< 26.3% of the maximum score) and a partial Mayo score < 3 (< 33.3% of the maximum score).	Authors' conclusion: 'Screening for variants in TPMT did not reduce the proportions of patients with hematologic adverse drug reactions (ADRs) during thiopurine treatment for IBD. However, there was a 10-fold reduction in hematologic ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriers who did not, without differences in treatment efficacy.'

ref. 14, continuation	Genotype-guided versus standard treatment: all: AA IM+PM: AA#	General adverse events included dizziness, shivers, fever, and general malaise. Gastrointestinal adverse events included stomach ache, diarrhoea, reduced appetite, nausea, and vomiting. Hepatic adverse events included cholestasis, cholangitis, hepatitis, and steatosis. Dermatological adverse events included hair loss, warts, and skin rash. Co-treatment with allopurinol was excluded, but 49.6% of patients used mesalazine concomitantly. In addition, corticosteroids (81.7% of patients) and biologicals were used as co-medication. The use of mesalazine and corticosteroids did not differ significantly between the genotype-guided and standard treatment group, but the use of biologicals was higher in the standard treatment group (7.4% versus 3.7%). The use of biologicals was associated with an increased risk of hematologic adverse events. The study was designed to have 80% power with inclusion of 388 patients per treatment arm and a reduction in hematologic adverse event rate of 50% (event rate of 11% in the non-genotyped group and 5.5% in the genotyped group). Genotyping: <table><tr><td>Genotype-guided group</td><td>Standard treatment group</td></tr><tr><td>- 365x NM</td><td>- 340x NM</td></tr><tr><td>- 39x IM</td><td>- 38x IM</td></tr><tr><td>- 1x PM</td><td></td></tr></table> Results: <table><tr><th colspan="4">Results compared to the standard treatment group (controls):</th></tr><tr><th colspan="2"></th><th></th><th>value for controls</th></tr><tr><td rowspan="3">% of patients with hematologic adverse events</td><td colspan="2">NS</td><td>7.9%</td></tr><tr><td colspan="2">The result was also NS when: - patients on biologicals were excluded - only patients who started treatment were included - the median time to a hematologic adverse event was analysed - only events in the first 8 weeks were analysed</td><td></td></tr><tr><td colspan="2">The authors calculated that a randomized controlled trial with 42,556 participants would be needed to show a benefit for the entire intervention group (power of 80%).</td><td></td></tr><tr><td rowspan="2">% of patients who started treatment, with hematologic</td><td>NM</td><td>NS</td><td>6.6%</td></tr><tr><td>IM+</td><td>RR = 0.11 (95%</td><td>22.9%</td></tr></table>				Genotype-guided group	Standard treatment group	- 365x NM	- 340x NM	- 39x IM	- 38x IM	- 1x PM		Results compared to the standard treatment group (controls):							value for controls	% of patients with hematologic adverse events	NS		7.9%	The result was also NS when: - patients on biologicals were excluded - only patients who started treatment were included - the median time to a hematologic adverse event was analysed - only events in the first 8 weeks were analysed			The authors calculated that a randomized controlled trial with 42,556 participants would be needed to show a benefit for the entire intervention group (power of 80%).			% of patients who started treatment, with hematologic	NM	NS	6.6%	IM+	RR = 0.11 (95%	22.9%
		Genotype-guided group	Standard treatment group																																			
		- 365x NM	- 340x NM																																			
		- 39x IM	- 38x IM																																			
		- 1x PM																																				
		Results compared to the standard treatment group (controls):																																				
					value for controls																																	
		% of patients with hematologic adverse events	NS		7.9%																																	
			The result was also NS when: - patients on biologicals were excluded - only patients who started treatment were included - the median time to a hematologic adverse event was analysed - only events in the first 8 weeks were analysed																																			
			The authors calculated that a randomized controlled trial with 42,556 participants would be needed to show a benefit for the entire intervention group (power of 80%).																																			
% of patients who started treatment, with hematologic	NM	NS	6.6%																																			
	IM+	RR = 0.11 (95%	22.9%																																			

ref. 14, continuation	adverse events		PM	CI: 0.01-0.85) The result was also S when patients on biologicals were excluded.	
	% of patients with treatment induced remission			NS	67.4%
	median absolute change in erythrocyte sedimentation rate	NM		NS	-1.0
		IM+PM		- 8.0 (S)	0.0
	median percentage change in erythrocyte sedimentation rate	NM		NS	-6.3%
		IM+PM		NS	0.0%
	median absolute change in C-reactive protein			NS	-1.0
	median percentage change in C-reactive protein			NS	-22.9%
	% of patients with general adverse events			NS	43.1%
	% of patients with gastrointestinal adverse events			NS	71.2%
	% of patients with infections			NS	4.5%
	% of patients with hepatic adverse events			NS	7.1%
	% of patients with dermatologic adverse events			NS	23.3%
	% of patients with myalgia			NS	13.8%
	% of patients with hematologic adverse events			NS	16.4%
	% of patients with thiopurine use for up to 20 weeks			NS	69.3%
	% of patients with (temporary) thiopurine stop			NS	37.8%
	% of patients with signs of hepatotoxicity, pancreatitis or anemia based on blood levels			NS	25.9%, 22.2%, and 61.1%
	azathioprine starting dose	all		NS	2.2 mg/kg
		NM		NS	2.2 mg/kg
		IM+PM		x 0.52 (S)	2.1 mg/kg
	6-mercaptopurine starting dose	all		x 1.0 (S)	1.2 mg/kg
		NM		NS	1.2 mg/kg
		IM		x 0.50 (S)	1.2 mg/kg
	azathioprine dose in week 20	all		x 0.95 (S)	2.2 mg/kg
		NM		NS	2.2 mg/kg
		IM+PM		x 0.48 (S)	2.1 mg/kg
	6-mercaptopurine dose in week 20	all		NS	1.1 mg/kg
		NM		NS	1.1 mg/kg
		IM		x 0.55 (S)	1.1 mg/kg
	The median 6-TGN level after 8 weeks was within the therapeutic range for IM+PM on genotype-guided treatment and above therapeutic range for IM on standard				

ref. 14, continuation		treatment. The 6-TGN level was significantly different between the two groups. For NM, median 6-TGN levels after 8 weeks were around the lower limit of the therapeutic range for both genotype-guided and standard treatment. NOTE: Genotyping was for *2, *3A and *3C. These are the most important gene variants in this Dutch population.	
ref. 15, cytostat Lennard L et al. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol 2015;170:550-8. PubMed PMID: 25940902.	3	2387 patients, aged 1-25 years, with acute lymphoblastic leukaemia were treated with therapy including 6-mercaptopurine. The trial recommendation was to start PM on 10% of the 6-mercaptopurine protocol dose, and titrate to the protocol target cell counts. Median follow-up was 5 years 10 months (range 3 months to 10 years 1 month). 3% of patients had metabolite levels at the lower limit of detection or lacked measurable metabolites, suggesting non-compliance, 15% of these patients on multiple occasions. Patients classified as clinical high risk (NCI re-classified cohorts, high-risk cytogenetics or slow morphological early response) were not eligible for minimal residual disease (MRD) stratification. For the stratification of clinical standard and intermediate risk groups by bone-marrow minimal residual disease (MRD), MRD was measured after induction (day 29) and again after the recovery from consolidation but prior to the start of interim maintenance. Minimal residual disease low-risk patients were defined as those with no detectable disease and those patients who were MRD negative prior to interim maintenance. Indeterminate risk patients had detectable disease ($<0.01\%$ MRD = $<10^{-4}$ leukaemia cells) prior to interim maintenance; this group also included those patients with no MRD measurement. High risk patients had detectable disease ($\geq 0.01\%$) at the end of induction. TPMT genotypes were available for 791 high-risk MRD patients and 866 low-risk MRD patients. Treatment intensity randomizations of one or two delayed intensive blocks (reduced versus standard treatment) for low risk patients and standard treatment versus an intensive schedule for high-risk patients was applied. The delayed intensive blocks did not contain 6-mercaptopurine. Consolidation therapy for all patients, interim maintenance courses for clinical standard and intermediate risk patients, and maintenance therapy for all patients contained 6-mercaptopurine. Additional blood samples for metabolite monitoring were taken if non-compliance with oral 6-mercaptopurine was suspected or for patients unduly sensitive to mercaptopurine or tolerating mercaptopurine prior to dose escalation. Thiopurine metabolites were measured after a median of 17 weeks in 54% of NM, 58% of IM and all PM. For the 7 PM identified before treatment, thiopurine metabolites were measured after a median of 8 weeks (range 2 to > 12 weeks). Comparing the 2406 patients with thiopurine data (TPMT genotype and/or mercaptopurine metabolites) to 720 patients from the same trial with no data, there is some bias in the thiopurine dataset towards younger patients and those who are less high risk. Event-free survival (EFS) was defined as time to relapse, secondary tumour or death. Relapse-free survival (RFS) was defined as time to relapse (excluding those patients who did not achieve a remission or died during initial induction or consolidation chemotherapy). Overall survival (OS) was defined as time to death. Comparisons between groups were stratified by age, gender and white blood cell count at presen-	Authors' conclusion: 'In contrast to the preceding trial ALL97, there was no difference in event-free survival between the TPMT genotypes. In conclusion, refinements in risk stratification and treatment have reduced the influence of TPMT genotype on treatment outcome in a contemporary protocol.'

ref. 15, continuation		tation. To test the hypothesis that there is about a four-fold difference in event rates between TPMT *1/*3A and *1/*3C groups, as seen in Lennard, Br J Haematol 2015;169:228-40, 1845 patients over a six-year trial period will give over 95% power to detect this with similar event rates (55% and 14% for TPMT*1/*3C and TPMT*1/*3A patients respectively). The event-free survival in this study is higher than in Lennard, Br J Haematol 2015;169:228-40. There is over 85% power to detect a similar difference but with decreased event rates of 40% and 10%, and over 80% for 32% and 8% for TPMT *1/*3C and TPMT*1/*3A patients, respectively. Genotyping: - 2190x NM - 189x IM (3x *1/*2, 166x *1/*3A, 19x *1/*3C, 1x *1/*9) - 8x PM (of whom 7 identified pre-treatment) Results: <table border="1"> <thead> <tr> <th colspan="4">Results compared to NM (PM versus IM versus NM, unless indicated otherwise):</th></tr> <tr> <th></th><th></th><th></th><th>value for NM</th></tr> </thead> <tbody> <tr> <td rowspan="2">% of patients with 5-years event-free survival</td><td colspan="2">NS</td><td>88%</td></tr> <tr> <td colspan="2">The result was also NS: - when separate genotypes were compared to NM - within both the MRD high-risk and MRD low-risk group</td><td>MRD high-risk: 80.5% MRD low-risk: 95.4%</td></tr> <tr> <td>% of patients with 5-years relapse-free survival</td><td colspan="2">NS</td><td>92%</td></tr> <tr> <td>% of patients with 5-years overall survival</td><td colspan="2">NS</td><td>93%</td></tr> <tr> <td>median 6-mercaptopurine dose at time of metabolite measurement</td><td>IM</td><td>x 0.987 (S for the difference)</td><td>75 mg/m²</td></tr> <tr> <td>median 6-TGN</td><td>IM</td><td>x 2.41 (S for the difference)</td><td>312 pmol/8 x10⁸ RBC</td></tr> <tr> <td>median 6-methyl-mercaptopurines nucleotides (6-MMPN)</td><td>IM</td><td>x 0.28 (S for the difference)</td><td>14808 pmol/8 x10⁸ RBC</td></tr> <tr> <td>median maximum tolerated 6-mercaptopurine dose</td><td>PM</td><td>x 0.12 (range: x 0.11 - x 0.35)</td><td>Protocol: 75 mg/m²</td></tr> <tr> <td>median 6-TGN at maximum tolerated 6-mercaptopurine dose</td><td>PM</td><td>x 4.26 (range: x 3.11 - x 8.23)</td><td>312 pmol/8 x10⁸ RBC</td></tr> <tr> <td colspan="4">One PM, who lacked a pre-treatment blood sample, was identified during maintenance chemotherapy with a history of repeated cytopenias and an inability to tolerate mercaptopurine; 6-TGN level after 67% of protocol 6-mercaptopurine dose (50 mg/m²) for 6 weeks was 7.52 times the</td></tr> </tbody> </table>	Results compared to NM (PM versus IM versus NM, unless indicated otherwise):							value for NM	% of patients with 5-years event-free survival	NS		88%	The result was also NS: - when separate genotypes were compared to NM - within both the MRD high-risk and MRD low-risk group		MRD high-risk: 80.5% MRD low-risk: 95.4%	% of patients with 5-years relapse-free survival	NS		92%	% of patients with 5-years overall survival	NS		93%	median 6-mercaptopurine dose at time of metabolite measurement	IM	x 0.987 (S for the difference)	75 mg/m ²	median 6-TGN	IM	x 2.41 (S for the difference)	312 pmol/8 x10 ⁸ RBC	median 6-methyl-mercaptopurines nucleotides (6-MMPN)	IM	x 0.28 (S for the difference)	14808 pmol/8 x10 ⁸ RBC	median maximum tolerated 6-mercaptopurine dose	PM	x 0.12 (range: x 0.11 - x 0.35)	Protocol: 75 mg/m ²	median 6-TGN at maximum tolerated 6-mercaptopurine dose	PM	x 4.26 (range: x 3.11 - x 8.23)	312 pmol/8 x10 ⁸ RBC	One PM, who lacked a pre-treatment blood sample, was identified during maintenance chemotherapy with a history of repeated cytopenias and an inability to tolerate mercaptopurine; 6-TGN level after 67% of protocol 6-mercaptopurine dose (50 mg/m ²) for 6 weeks was 7.52 times the				Median dose versus protocol dose: PM: 12% Dose-corrected 6-TGN concentration versus NM: PM: 1128%
Results compared to NM (PM versus IM versus NM, unless indicated otherwise):																																																		
			value for NM																																															
% of patients with 5-years event-free survival	NS		88%																																															
	The result was also NS: - when separate genotypes were compared to NM - within both the MRD high-risk and MRD low-risk group		MRD high-risk: 80.5% MRD low-risk: 95.4%																																															
% of patients with 5-years relapse-free survival	NS		92%																																															
% of patients with 5-years overall survival	NS		93%																																															
median 6-mercaptopurine dose at time of metabolite measurement	IM	x 0.987 (S for the difference)	75 mg/m ²																																															
median 6-TGN	IM	x 2.41 (S for the difference)	312 pmol/8 x10 ⁸ RBC																																															
median 6-methyl-mercaptopurines nucleotides (6-MMPN)	IM	x 0.28 (S for the difference)	14808 pmol/8 x10 ⁸ RBC																																															
median maximum tolerated 6-mercaptopurine dose	PM	x 0.12 (range: x 0.11 - x 0.35)	Protocol: 75 mg/m ²																																															
median 6-TGN at maximum tolerated 6-mercaptopurine dose	PM	x 4.26 (range: x 3.11 - x 8.23)	312 pmol/8 x10 ⁸ RBC																																															
One PM, who lacked a pre-treatment blood sample, was identified during maintenance chemotherapy with a history of repeated cytopenias and an inability to tolerate mercaptopurine; 6-TGN level after 67% of protocol 6-mercaptopurine dose (50 mg/m ²) for 6 weeks was 7.52 times the																																																		

ref. 15, continuation		median value for NM (2347 pmol/8x10⁸ RBC). NOTE: The TPMT activity was measured in 48% of NM and 49% of IM. The median mercaptopurine metabolite concentrations measured in the NMs with a TPMT activity comparable to the IMs (6-TGN: 317 pmol/8x10⁸ RBC, 6-MMPN: 15,937 pmol/8x10⁸ RBC) were similar to the concentrations measured in the NMs with a TPMT activity higher than the IMs (6-TGN: 311 pmol/8x10⁸ RBC, 6-MMPN: 14,380 pmol/8x10⁸ RBC) and significantly different from the metabolite concentrations recorded for IMs (6-TGN: 747 pmol, 6-MMPN: 3407 pmol) (S). This has been mainly attributed to the undue influence of the disease process and chemotherapy on red blood cell TPMT enzyme activity. In this patient group, genotyping provides more information than phenotyping. NOTE: Genotyping was by sequencing exons 5, 7 and 10, detecting *2, *3A, *3B, *3C and *9. These are the most important gene variants in this British population.	
ref. 16 - cytostat Lennard L et al. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol 2015;169:228-40. PubMed PMID: 25441457.	3 IM: E	A total of 709 children with acute lymphoblastic leukaemia were treated with mercaptopurine for 2-3 years. The initial dose was 75 mg/m² for NM and IM, and 7.5 mg/m² for PM. Mercaptopurine was administered in combination with methotrexate, vincristine and either dexamethasone or prednisone. Relevant co-medication was not excluded. Clinical outcome measures were only determined in combination with a group receiving thioguanine as the thiopurine (n = 426) and were available for 61% of the patients. A dose of 100% was defined as the initial dose of the thiopurine for NM/IM. Genotyping (mercaptopurine only): - 636x NM (*1/*1) - 71x IM (3x *1/*2, 53x *1/*3A, 12x *1/*3C, 1x *1/*9, 1x *1/*32, 1x *1/*33) - 2x PM (1x*2/*3A, 1x *3C/*3C) IM versus NM: Mercaptopurine or thioguanine: - duration of cytopenia-induced thiopurine dose interruptions increased by 34% (from 15.5% to 20.8% of the total duration) (S) - neutropenia increased by 8.1% (from 23.4% to 25.3% of the total duration) (S) - thrombocytopenia increased by 159% (from 3.4% to 8.8% of the total duration) (S) - the average daily thiopurine dose decreased by 10% (from 78.0% to 70.4% of the initial dose) (S) - 5-year EFS (event-free survival, with an event defined as time to relapse or death) increased by 10% for *1/*3A versus NM (from 80% to 88%) (S), but multivariate regression analysis did not identify a significantly decreased risk of relapse or death for all IM patients except for those with *1/*3C (NS) - 5-year EFS decreased by 34% in *1/*3C patients versus NM patients (from 80% to 53%) (S), and multivariate regression analysis showed an increased risk of relapse or death (HR = 3.2; 95% CI: 1.5-6.8) (S) There was no difference between *1/*3C and *1/*3A in average daily dose or incidence of cytopenia. However, there was evidence of poor compliance in the mercaptopurine group (see below).	Authors' conclusion: "TPMT*1/*3A heterozygotes had a better event-free survival than TPMT wild-type patients. Thiopurine induced cytopenias were not detrimental to treatment outcome. The TPMT heterozygotes tolerated significantly lower average % doses than the TPMT wild-type patients (70% vs 78% for TPMT wild-type, a daily-dose difference of 6 mg/m² per day mercaptopurine). However, the range of thiopurine doses tolerated was wide, with the upper and lower limits similar for both TPMT genotypes. These findings do not support any change in the prescribing criteria (both genotypes start at the same standard protocol dose and titrate to toxicity)."

ref. 16, continuation	PM: A (2)	- no difference in secondary tumours (median follow-up 11.3 years) (NS) Mercaptopurine only: - Increase in the median 6-TGN concentration by 109% (from 360 to 754 pmol/8x10⁸ RBCs) (S) measured at a non-significantly different median dose (from 75 to 74 mg/m²) (NS) - the median 6-TGN concentration was higher for *1/*3A than for *1/*3C, despite similar doses and TPMT activity (802 and 608 pmol/8x10⁸ RBCs; increase versus NM of 123% and 69%) (S). There was also a trend for lower concentrations of the metabolite MMP for *1/*3C, suggesting that the lower 6-TGN concentrations are caused by a lower therapy compliance. PM versus NM: Mercaptopurine only: - The eventual dose for *2/*3A was 5% of the dose in NM patients (7.5 mg/m² every other day) and 20% (15 mg/m²) for *3C/*3C. - At these doses, the 6-TGN concentrations were a factor 4.6 and 5.0 higher, respectively, than the median 6-TGN concentration for NM (1670, 1784 and 360 pmol/8x10⁸ RBCs respectively). NM on mercaptopurine or thioguanine: - The average daily thiopurine dose for *2/*3A was 16% of the dose in NM patients (12.6% of the initial dose for NM/IM). - The average daily thiopurine dose for *3C/*3C was 25% of the dose in NM patients (19.5% of the initial dose). N.B.: Genotyping was performed for *2, *3A, *3B and *3C. Exons 3 to 10 were sequenced to identify new or rare variants (*9, *21, *32-*34).	Dose versus NM: PM: 12.5%
ref. 17 - cytostat, dose PM Belen BF et al. Severe myelotoxicity associated with thiopurine S-methyltransferase*3A/*3C polymorphisms in a patient with pediatric leukemia and the effect of steroid therapy. Turk J Haematol 2014;31:399-402. PubMed PMID: 25541649.	2 PM: E	A fifteen year old girl with acute lymphoblastic leukaemia developed two prolonged episodes of myelosuppression shortly after starting chemotherapy with mercaptopurine 60 mg/m² per day, cytarabine and cyclophosphamide. Despite the use of colony stimulating factors, she developed neutropenia (< 0.8x10⁹ cells/mm³) on maintenance therapy with mercaptopurine and methotrexate at doses amounting to 25% of the doses stated in the protocol. Her TPMT genotype was *3A/*3C. In addition, she was heterozygous for the MTHFR polymorphisms C677T and A1298C. For the MTHFR polymorphisms, it is not clear whether they form an additional risk factor for haematotoxicity. Pancytopenia and transfusion-dependency continued after reduction of the doses of mercaptopurine and methotrexate to 10% of the doses listed in the protocol. Intensification therapy with high-dose methotrexate and mercaptopurine at 5% of the standard dose (2.5 mg/m² per day) was possible with weekly transfusions to keep the blood platelets above 10x10⁹/L. Maintenance therapy over a period of 5 weeks was possible at 5-10% of the standard dose of mercaptopurine and 8-16% of the standard dose of methotrexate.	Authors' conclusion: "Compound heterozygosity for TPMT *3A/3C may be associated with severe bone marrow hypoplasia, even with minimal amounts of MP, in children with ALL." Dose versus NM: PM: 7.5%
ref. 18 - imm sup, kinetics Kim MJ et al. Monitoring thiopu-	3	109 children and adolescents with inflammatory bowel disease were treated with azathioprine. Relevant co-medication was not excluded.	Authors' conclusion: "There were no statistical differen-

rine metabolites in Korean pediatric patients with inflammatory bowel disease. Yonsei Med J 2014;55:1289-96. PubMed PMID: 25048487. ref. 18, continuation	IM: AA PM: A (2)	Genotyping: - 102x NM (*1/*1) - 6x IM (4x *1/*3C, 1x *1/*6, 1x *1/*16) - 1x PM (*3C/*3C) IM versus NM: - dose-corrected 6-TGN concentration increased by 183% (from 347.3% to 983.0 pmol/8x10⁸ RBC per mg/kg per day) (NS) PM versus NM: - dose-corrected 6-TGN concentration increased by 598% (from 347.3% to 2425.6 pmol/8x10⁸ RBC per mg/kg per day) For all TPMT genotypes, the required dose was lower for East Asians than for Western patients. N.B.: The TPMT gene was sequenced for the identification of variants. *3C is the most common gene variant in this East Asian population group.	ces in initial AZA dose between the group of wild type TPMT and TPMT mutation. However, the 6-TGN concentration was 416.8±271.7 pmol/8x10⁸ RBC in patients with wild type TPMT and 1822.9± 1493.9 pmol/8x10⁸ RBC in TPMT mutation (p=0.001)." Dose-corrected 6-TGN concentration versus NM: IM: 283% PM: 698%
ref. 19 - cytostat Levensen M et al. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. Pediatr Blood Cancer 2014;61:797-802. PubMed PMID: 24395436.	3 IM with 67% of the standard initial dose: AA	A total of 674 children with acute lymphoblastic leukaemia were treated with mercaptopurine for 2 or 2.5 years. The initial dose was 75 mg/m² for NM, 50 mg/m² for IM and 5-10 mg/m² for PM. Mercaptopurine was administered in combination with methotrexate, vincristine and dexamethasone. The duration of the mercaptopurine treatment and the additional cytostatic treatments was dependent on the risk group. Relevant co-medication was not excluded. Data were compared to those from a study in which IM received an initial dose of 75 mg/m² (n = 601, of which 75 with an IM or PM phenotype or genotype). Genotyping: - 617x NM - 56x IM - 1x PM IM+PM with reduced initial dose compared to NM with standard initial dose: - no difference in EFS at 8 years (NS) - no difference in the 8-year risk of developing a new cancer (NS) - no difference in the 8-year risk of cancer relapse (NS). The same result was observed after correction for confounding factors in Cox regression analysis. IM+PM with reduced initial dose compared to phenotypically or genotypically IM+PM with standard initial dose: - decrease in the number of patients who developed a new cancer by 100% (from 4 to 0), following exclusion of 2 IM who received a standard initial dose after all (S). In the total group (including the IM who received the standard initial dose after all and developed a new cancer), there was no significant difference in the 8-year risk of developing a new cancer (NS). - increase in the 8-year risk of cancer relapse by a factor 2.9 (from 6.7% to 19.7%) (S) N.B.: Genotyping was performed for *3A, *3B and *3C.	Authors' conclusion: "This study indicates that reducing 6MP starting dose for patients with TPMT^{LA} may reduce second malignant neoplasma risk but lead to a relapse risk similar to that of patients with TPMT^{WT}. Given the low relapse risk for patients with TPMT^{LA} receiving starting 6MP doses of 75 mg/m² in NOPHO ALL92, the present study suggests that patients with TPMT^{LA} or TPMT^{WT} both should be treated with starting doses of 75 mg 6MP/m²/day. Since longer duration of therapy has been associated with second malignant neoplasma, one option could be to shorten the duration of maintenance therapy for patients with TPMT^{LA} to 2 years as given in BFM protocols."

ref. 20 - cytostat, dose PM Demlova R et al. Augmenting clinical interpretability of thiopurine methyl-transferase laboratory evaluation. Oncology 2014;86:152-8. PubMed PMID: 24643197.	2 PM: E	A thirteen year old boy with acute lymphoblastic leukaemia developed very severe myelosuppression with recurrent cerebral haemorrhages upon treatment with standard doses of mercaptopurine, cytarabine and cyclophosphamide. His genotype turned out to be *2/*3A. The patient was treated successfully with 6.5% of the standard dose of mercaptopurine.	Authors' conclusion: "Extreme and life-threatening toxicity was observed in the compound heterozygote patient." Dose versus NM: PM: 6.5%
ref. 21 – imm supp, dose PM Lee MN et al. Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C. Yonsei Med J 2013;54:1545-9. PubMed PMID: 24142665.	2 PM: E	An eighteen year old male with Crohn's disease developed neutropenia ($1.0 \times 10^9/L$) and leukopenia ($2.8 \times 10^9/L$) two weeks after starting a standard dose of azathioprine (1.8 mg/kg per day) and mesalazine 55.6 mg/kg per day. Despite reduction of the azathioprine dose to 0.9 mg/kg per day, the neutropenia and leukopenia had become worse three weeks later ($0.19 \times 10^9/L$ and $1.9 \times 10^9/L$ respectively). After starting again with azathioprine (0.8 mg/kg per day), without mesalazine, the patient again developed neutropenia after the dose was increased to 1.2 mg/kg per day. The patient was found to have the *3C/*3C genotype. Based on 6-TGN concentrations, the patient was given azathioprine 0.2 mg/kg per day for 1.5 years and then 0.1 mg/kg per day for 0.5 years without further episodes of neutropenia or leukopenia.	Dose versus NM: PM: 8.3%
ref. 22 - cytostat, dose PM Kim H et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One 2012;7:e45558. PubMed PMID: 23029095.	3 PM: A (2)	Out of a total of 100 children with acute lymphoblastic leukaemia who received maintenance therapy with mercaptopurine and methotrexate, 93 were NM and 1 was PM (*2/*2). The planned dose was 50 mg/m ² per day. The required dose is lower for East Asians than for Western patients. Relevant co-medication was not excluded. PM versus NM: - the PM exhibited only mild toxicity - the dose in the last cycle of the maintenance therapy was 62% for PM and median 50% for NM (increase by 24%) N.B.: Genotyping was performed for *2, *3A, *3B and *3C. In this Asian population group, *3C was the most common gene variant.	Dose versus NM: PM: 124%
ref. 23 - imm sup Booth RA et al. Assessment of thiopurine S-methyl-transferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154:814-23, W-295-8. PubMed PMID: 21690596.	3	Meta-analysis of 31 studies into toxicity caused by azathioprine or mercaptopurine in a total of 3,638 patients with autoimmune diseases (including 260 IM and 19 PM). Leukopenia was the measure of outcome in 18 studies involving a total of 1,825 patients, including 105 IM and 7 PM. Of these 18 studies, Jun 2005 and Zelinkova 2006 have also been included separately in this risk analysis. Of these 18 studies, 10 have also been included in the meta-analysis of Higgs 2010 (Bezier 2008, Stocco 2007, Winter 2007, De Ridder 2006, Zelinkova 2006, Jun 2005, Derijks 2004, Hibi 2003, Jojic 2003, and Ishioka 1999) and 4 in the meta-analysis of Dong 2010 (Stocco 2007, Winter 2007, Zelinkova 2006, and Derijks 2004). Only studies in which at least *2, *3A, *3B and *3C were genotyped were included in the meta-analysis. Risk for bias was evaluated by using generic items that assessed selection, performance, detection, and attrition bias, as well as confounding and potential for financial conflict of interest. Each study was given an overall risk-for-bias assessment of good (low risk), fair, or poor (high risk). Most	Authors' conclusion: "Compared with non-carriers, heterozygous and homozygous genotypes were both associated with leukopenia."

ref. 24, continuation

Genotype-guided versus standard treatment: AA

(2)
PM: D

months of therapy from 14 to 8%. This required 500 patients in each arm. However, because neutropenia rates in the first 100 patients were considerably lower than initially predicted (1.3%), the study was resized to have 80% power to detect a 40% reduction in stopping azathioprine due to occurrence of an adverse drug reaction in the first 4 months of treatment. This required a total of 330 patients.

Genotyping:

Genotype-guided group	Standard treatment group
- 148x NM	- 150x NM
- 19x IM	- 15x IM
	- 1x PM

Results:

Results compared to the standard treatment group (controls):			
			value for controls
% of patients stopping azathioprine due to adverse events	NS		27.7%
% of patients with any adverse event	NS		32.1%
% of patients with hepatotoxicity	x 2.3 (S, but NS after correction for multiple comparisons)		5.0%
	Hepatotoxicity was only observed in NM.		
% of patients with severe neutropenia	NS		0.6%
	The only patient with severe neutropenia was the only PM. This patient experienced severe, early-onset nonfatal neutropenia after start of standard treatment (starting dose 0.6 mg/kg per day).		
% of patients with moderate neutropenia	NS		0.0%
prevalence of each of the other tested adverse events	NS		
Crohn's disease severity after 4 months (score on the Harvey Bradshaw Index)	NS		4.5
azathioprine starting dose	NM	NS	0.86 mg/kg
	IM+PM	x 0.66 (S)	0.93 mg/kg
azathioprine dose at 4 months	NM	NS	1.74 mg/kg
	IM	NS	1.62 mg/kg

Results for IM (on genotype-guided or standard treatment) compared to NM:		
		value

ref. 24, continuation		<table><tr><td>% of patients stopping azathioprine due to adverse events</td><td>NS</td><td>for NM 28.2%</td></tr><tr><td rowspan="2">% of patients with moderate or severe neutropenia</td><td>NS</td><td rowspan="2">0.70%</td></tr><tr><td>The result was also NS when follow-up of patients who were still taking azathioprine at 4 months was extended to 12 months.</td></tr></table>	% of patients stopping azathioprine due to adverse events	NS	for NM 28.2%	% of patients with moderate or severe neutropenia	NS	0.70%	The result was also NS when follow-up of patients who were still taking azathioprine at 4 months was extended to 12 months.	
	% of patients stopping azathioprine due to adverse events	NS	for NM 28.2%							
	% of patients with moderate or severe neutropenia	NS	0.70%							
The result was also NS when follow-up of patients who were still taking azathioprine at 4 months was extended to 12 months.										
		NOTE: The authors indicate that a recommendation for TPMT testing has been added to clinical guidelines of the British Association of Dermatology and the British Society for Rheumatology/British Health Professionals in Rheumatology Standards (Anstey AV et al. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:1123-32. PubMed PMID: 15606506; and Chakravarty K et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008;47: 924-5. PubMed PMID: 16940305). NOTE: Genotyping was for *2, *3A, *3B and *3C. These are the most important gene variants in this British population. No rare TPMT variant alleles were identified in any patient by a screen of all previously reported TPMT variants.								
ref. 25 - imm sup Dong XW et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010;16:3187-95.	3 									

ref. 25, continuation		100 patients were included. There was no evidence of substantial publication bias. The funnel plot was slightly asymmetrical in distribution, but Egger's regression test suggested no significant asymmetry of the funnel plot.	
ref. 26 - imm sup Hindorf U et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52:106-11.	3 IM: A	Thiopurine therapy was not withdrawn in 143 patients (134x azathioprine, 9x mercaptopurine) out of 175 patients with auto-immune hepatitis (156x NM, 12x IM, 1x genotypic NM/phenotypic IM, 2x genotypic IM/phenotypic NM, 5 unknown genotype). Dose and 6-TGN concentration were determined for these 143 patients. Co-medication: prednisolone, otherwise unknown. Phenotypically IM versus phenotypically NM: - decrease in dose by 15% (from 1.3 to 1.1 mg/kg per day) (NS). - increase in 6-TGN concentration by 84% (from 112 to 206 pmol/8x10⁸ RBC) (S) - no increase in the percentage of patients with adverse events (from 16% to 20%) (NS). N.B.: Lower doses are used in the case of auto-immune hepatitis than for Crohn's disease and ulcerative colitis (approx. half), meaning that bone marrow toxicity plays a less important role here.	Dose versus NM (corrected for 6-TGN concentrations): IM: 46%
ref. 27 - imm sup Sheffield LJ et al. Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics 2009;10:1091-9.	3 IM: A	A total of 126 patients with Crohn's disease or ulcerative colitis (113x NM, 13x IM), who used thiopurines ≥ 3 months, of which ≥ 4 weeks at a stable dose. No co-medication reported. IM versus NM: - decrease in dose by 22% (from 2.02 to 1.58 mg/kg azathioprine-equivalents per day) (S) - increase in 6-TGN concentration by 83% (from 341.5 to 624.9 pmol/8x10⁸ RBC) (S) N.B.: Genotyping was performed for *2, *3A and *3C.	Dose versus NM (corrected for 6-TGN concentrations): IM: 43%
ref. 28 - imm sup Ansari A et al. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 2008;28:749-57.	3 IM: AA PM: A(2)	A total of 31 patients with Crohn's disease (26x NM, 4x IM, 1x PM), who used azathioprine ≥ 2 months. Co-medication: mesalazine (n=15). IM versus NM: - decrease in median dose by 50% (from 2.0 to 1.0 mg/kg azathioprine per day) (NS) PM versus NM: - decrease in dose by 95.5% (from median 2.0 to 0.09 mg/kg azathioprine per day) (NS) N.B.: Genotyping was performed for *2, *3A and *3C.	Dose versus NM: IM: 50% PM: 4.5%
ref. 29 - imm sup Gardiner SJ et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008;6:654-60.	3	A total of 52 patients with Crohn's disease or ulcerative colitis (47x NM, 5x IM), were treated with azathioprine or mercaptopurine for 9 months. The average initial dose was 1 mg/kg azathioprine-equivalents per day. The dose was adjusted according to the 6-TGN concentration (target value 235-450 pmol/8x10 ⁸ RBC) and the patient's clinical condition. Co-medication: mesalazine (78% of the patients). The median TPMT activity did not differ between the groups that did and did not use mesalazine. IM versus NM:	

[illegible]

Two cases of thio-purine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 2006;62:473-6. ref. 35, continuation	PM: D PM: A	the start of azathioprine 100 mg/day (approx. 1.4 mg/kg per day) for Crohn's disease. Recovery occurred after withdrawal of AZA and following infusions of RBCs, platelets and filgrastim. Due to an error, the patient was again given azathioprine 100 mg/day 7 months later and again developed severe myelosuppression. He was found to be PM (*3/*3). - Patient 2 was found to be *3/*3 four days after starting azathioprine 50 mg/day (0.64 mg/kg per day) for ulcerative colitis. Azathioprine was stopped. After six months, treatment was started with azathioprine 12.5 mg 2x per week (equivalent to 0.05 mg/kg per day). This treatment resulted in clinical improvement within six months and 6-TGN concentrations of 250-400 pmol/8x10 ⁸ RBC (within the target range of 235-450 pmol/8x10 ⁸ RBC).	Maintenance dose versus a standard dose of AZA 2-2.5 mg/kg per day: PM: 2.2%
ref. 36 - imm sup Kurzawski et al. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT *3A/*3C). Transpl Int 2005;18:623-5.	2 PM: E	A kidney transplant patient developed myelosuppression two months after starting azathioprine (200 mg on day 1, 150 mg/day on day 2-10, followed by 50 mg/day) + cyclosporine (500 mg/day on day 1-8, followed by 350 mg/day) + prednisone (45 mg/day, gradual reduction to 20 mg/day after 2 weeks). Co-medication: acetylsalicylic acid 500 mg/day, verapamil, co-trimoxazole and cefuroxime. Recovery occurred after withdrawal of AZA. The patient again developed myelosuppression three weeks after starting AZA again (initially 75 mg/day, then reduced to 50 mg/day). AZA was replaced by mycophenolic acid. The patient was found to be a *3A/*3B.	Authors' conclusion: "Evaluation of TPMT polymorphism in patients treated with thiopurine drugs should be mandatory in order to optimize therapy."
ref. 37 - imm sup Fabre MA et al. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transpl Int 2004;17:531-9.	4 IM: B high NM: A	172 kidney transplant patients (160x NM, 12x IM (11x *1/*3A, 1x *1/*3C)), received azathioprine (initial dose 1.5 mg/kg per day) in combination with cyclosporine and prednisolone for 1 year. Co-medication: acetylsalicylic acid 75 mg/day during the 1 st month, co-trimoxazole. Patients with allopurinol co-medication were excluded. - No serious adverse events, such as bone marrow aplasia or hepatotoxicity occurred. IM versus NM: - increase in the percentage of patients requiring dose reduction due to leukopenia < 4.0x10 ⁹ /L from 30% to 58% (S by 93%) - decrease in the average dose after 1 year versus the initial dose from 82.6% to 67.9% (NS) - number of patients with ≥ 1 acute rejection episode is comparable: 50% versus 43% (NS) - NM with ≤ 10 "variable number tandem repeats" in their TPMT promoters versus NM with ≥ 11 repeats (n=22): - decrease in the percentage of patients requiring dose reduction from 59% to 25% (S by 58%) - increase in the average dose after 1 year versus the initial dose from 68.9% to 84.6% (S by 23%) - number of patients with ≥ 1 acute rejection episode is comparable: 41% versus 50% (NS) N.B.: The relationship between promoter polymorphisms and TPMT activity is controversial. Previous research has demonstrated an inverse relationship between <i>in vitro</i> TPMT activity and total number of repeats.	Authors' conclusion: "We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter TPMT polymorphisms influence the dose tolerated."
ref. 38 - imm sup Geary RB et al. Thiopurine S-	3 [#]	50 patients with inflammatory bowel disease, who had to stop azathioprine or 6-mercaptopurine due to adverse events,	Authors' conclusion: "There was a slight

methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400. ref. 38, continuation	IM: AA PM: E(2)	were compared to 50 patients who tolerated azathioprine/6-mercaptopurine (dose unknown). - The 50 intolerant patients were found to be 44x NM, 5x IM (5x *1/*3) and 1x PM (*3/*3). The 50 tolerant patients were found to be 47x NM and 3x IM (*1/*3). - There was a trend towards more adverse events for IM + PM (NS). - Of the two patients with myelosuppression, one was IM and the other PM. The PM had severe pancytopenia, necessitating hospital admission. Hospital admission was also necessary for the IM. - The patients with the most common adverse event (hepatitis, 30%) were all NM. NB: *3 is *3A or *3C.	trend for more frequent TPMT mutations in the patients with adverse reactions, but this was not statistically significant. Most patients with reactions did not have gene mutations."
ref. 39 - imm sup Gilissen LP et al. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004;16:705-10.	2 IM: A PM: D	This article describes 5 cases, of which 2 with TPMT polymorphisms (1x IM (*1/*3A), 1x PM (*3A/*3A)). - Patient with *1/*3A genotype (60 years, ulcerative colitis) received 6-mercaptopurine 50 mg/day (0.7 mg/kg per day) + olsalazine 1000 mg 3x per day. After two months, it was decided to reduce the 6-MP to 25 mg per day, because the 6-TGN concentrations (628 pmol/8x10⁸ RBC) were high compared to the 6-MMP concentrations (362 pmol/8x10⁸ RBC). At this dose, the 6-TGN concentration was 417 pmol/8x10⁸ RBC, whilst 6-MMP was not detectable. Disease activity was in remission. - Patient with *3A/*3A genotype (32 years, ulcerative colitis) received 6-mercaptopurine 50 mg/day (0.5 mg/kg per day). Therapy was stopped due to suspected PM phenotype, because 6-TGN concentrations were extremely high (1284 pmol/8x10⁸ RBC). The patient was then treated in a different hospital with azathioprine 50 mg/day and developed severe leukopenia after several weeks. Treatment with 6-thioguanine is being considered.	Authors' conclusion: "Heterozygous patients like case 3 should have a dose reduction and intensive TDM, while homozygous poor metabolizers (TPMT=L) like case 4 are candidates for treatment with 6-TG or a significant dose reduction, according to a recent report." Maintenance versus initial dose: IM: 50%
ref. 40 - imm sup Kaskas BA et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52:140-2.	2 PM: F	3 cases with Crohn's disease: - Patient 1 developed severe myelosuppression 8 weeks after the start of azathioprine 1.3 mg/kg per day. Recovery occurred after withdrawal of AZA. 4 years later, AZA 0.29 mg/kg per day for 7 months had a good therapeutic effect. He was found to be PM (*3A/*3A). - Patient 2 developed tonsillitis with moderate leukopenia 1.5 years after starting azathioprine 1 mg/kg per day. Recovery occurred after withdrawal of AZA. Five months later she received AZA 0.25 mg/kg per day + methylprednisolone (dose unknown). Due to very high 6-TGN concentrations (1014 pmol/8x10⁸ RBC), the AZA was reduced to 0.20 mg/kg per day. Following a single infusion with infliximab, the patient was in continuous remission for over a year, without adverse events, on AZA 0.16 mg/kg per day + budesonide 9 mg/day. She was found to be PM (*3A/*3A). - Patient 3 was asymptomatic for 7 years after starting azathioprine 0.71 mg/kg per day. After genotyping (PM: *3A/*3C), the AZA was reduced to 0.26 mg/kg per day. 6-TGN concentrations were 797-884 pmol/8x10⁸ RBC after dose reduction.	Authors' conclusion: "We illustrate this with three cases where treatment has been successful and toxicity has been avoided by carefully titrating the drug dose. Thus very low TPMT activity demands pharmacogenetically guided dosing." Maintenance versus initial dose: PM: 16-37% Maintenance dose versus a standard dose of AZA 2-2.5 mg/kg per day: PM: 11%

ref. 43, continuation		- There was no significant difference in the number of leukocytes between individuals who were using AZA in combination with mesalazine and individuals who were using AZA alone. The distribution of TPMT activity and AZA doses was comparable in the groups with and without co-medication. N.B.: TPMT activity was partially determined by phenotyping (42%) of the patients and partially by genotyping.	
ref. 44 - imm sup Pandya B et al. Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients. Transplant Proc 2002;34:1642-5.	4 IM: C	88 kidney transplant patients (76x NM, 12x IM (6x *1/*3A, 3x *1/*3B, 3x *1/*3C)), were treated with azathioprine (initial dose 2.0 mg/kg per day). Patients with allopurinol or anti-thymocyte globulin as co-medication and patients with active cytomegalovirus infection or other diseases were excluded from the analysis. IM versus NM: - increase in the percentage of patients that developed leukopenia < 3.5x10⁹/L from 16% to 58.3% (S by 264%) - decrease in the average leukocyte concentration from 7.2x10⁹/L to 4.0x10⁹/L (S by 44%) - larger proportion of patients stopped with AZA within three months due to leukopenia < 3.5x10⁹/L (S) *1/*3A versus *1/*3B versus *1/*3C: - 5/6 (83%) versus 2/3 (67%) versus 0/3 (0%) of the patients developed leukopenia (significance not reported)	Authors' conclusion: "This shows that TPMT genotyping can be a quick and easy way to screen patients before initiating azathioprine therapy in renal transplant recipients and may be a valuable aid in clinical decision making to reduce the risk of haematologic side effects."
ref. 45 - imm sup Campbell S et al. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002;16:389-98.	3 IM: A	TPMT activity was determined in 87 patients with inflammatory bowel disease, of which 63 were using azathioprine and 24 had stopped using azathioprine due to adverse events. Co-medication: included mesalazine. - The average TPMT activity was lower in patients who had stopped treatment due to neutropenia than in patients who developed other adverse events (S) - The average TPMT activity was not lower in the AZA-intolerant patients than in the patients using AZA. - In a group of 34 patients who used low-dose AZA for more than one year, the average TPMT activity was lower for the patients who did not exhibit any exacerbations versus the patients with exacerbations: 19.8 versus 27.6 nmol/mL RBC per hour (S, decrease by 28%). The AZA dose (median 1.5 mg/kg per day) and the median duration of the treatment was comparable in both groups. - In this group, the time to first exacerbation was longer for IM than for NM (S). - For the group of 63 patients who, on average, used a higher AZA dose (median 1.75 mg/kg per day), the same trend was observed in the relationship between time to first exacerbation and TPMT activity (NS).	Authors' conclusion: "The mean thiopurine methyltransferase activity was significantly lower in patients on a low dose of azathioprine in remission compared with those who relapsed. The thiopurine methyltransferase activity was significantly lower in patients who discontinued azathioprine due to neutropenia than in those who discontinued due to other side effects."
ref. 46 - imm sup Colombel JF et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.	3	A total of 41 patients with Crohn's disease, who developed leukopenia <3.0x10⁹/L or thrombocytopenia <100 x10⁹/L during treatment with azathioprine 50-200 mg/day (median 125 mg/day) or 6-mercaptopurine 50-150 mg/day (median 62.5 mg/day). Following myelosuppression, the treatment was stopped in 83% of the patients and the dose was reduced by ≥ 50% in 17% of the patients. Co-medication varied. - four patients (10%) were found to be PM (1x *2/*3A, 1x *3A/*3A, 1x *3A/*3C, 1x *3C/*3C)	Authors' conclusion: "Twenty-seven percent of patients with CD and myelosuppression during azathioprine therapy had mutant alleles of the TPMT gene associated with

Gastroenterology 2000;118:1025-30. ref. 46, continuation	IM+PM: AA	seven patients (17%) were found to be IM (3x *1/*3A, 2x *1S/*3A, 1x *1/*2, 1x *1/*3C) 29 patients (71%) were found to be NM and one patient had a previously unknown allele (*1/*10). Total: 27% IM + PM versus 10% in a European control population (significance unknown). - severe leukopenia ($<2.0 \times 10^9/L$) occurred in 3/4 PM patients (75%) 2/7 IM patients (29%) 12/29 NM patients (41%) (significance unknown) - there was no clear correlation between AZA/6-MP dose and the severity of leukopenia PM versus NM: - bone marrow toxicity after median 1 month versus median 3 months. IM versus NM: - bone marrow toxicity after median 4 months versus median 3 months.	enzyme deficiency. Myelosuppression is more often caused by other factors. Continued monitoring of blood cell counts remains mandatory in patients treated with azathioprine."
ref. 47 - imm sup Black AJ et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8.	3 IM: C	A total of 66 patients (61x NM, 5x IM (5x *1/*3A)) with rheumatic conditions were treated with azathioprine 2-3 mg/kg per day (sometimes in combination with corticosteroids). IM versus NM: - decrease in median therapy duration from 39 to 2 weeks (S by 95%) - increased frequency of leukopenia $<3.5 \times 10^9/L$ as the cause of therapy withdrawal from 0% to 100%. No haematological abnormalities were observed in NM. The reasons for therapy withdrawal included other adverse events (nausea, hepatotoxicity) (33% of the patients) and lack of efficacy (30%).	Authors' conclusion: "Analysis of thiopurine methyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine."
ref. 48 - imm sup/ cytostat Higgs JE et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010;11:177-88.	3	Systematic review of 67 studies and meta-analysis of the data from 47 studies with patients who used azathioprine or mercaptopurine for various conditions. The total number of patients in the meta-analysis was 4,306, of which 434 were IM (determined by phenotyping or genotyping). No poor quality studies were included in the meta-analysis. Of the studies in the meta-analysis, ten were included as a reference in this risk analysis (Black 1998, McLeod 1999, Ansari 2002, Langley 2002, Pandya 2002, Gearry 2003, Fabre 2004, Jun 2005, Stocco 2005 and Zelinkova 2006). It was not explicitly stated whether the meta-analysis was performed with a fixed- of random-effects model, but the statement that pooling studies with an I^2 of less than 50% has been suggested as acceptable, as values of greater than 50% indicate substantial heterogeneity, suggests it was with a fixed-effects model. Because it concerns studies in humans, a random-effects model should have been chosen prospectively. Prospective registration of the protocol was not mentioned. The search and selection strategy was transparent and data extraction was standardised. Quality of the included studies was assessed using published guidelines specifically designed to assess the quality of pharmacogenetic studies (Jorgensen AL and Williamson PR. Methodological quality of pharmacogenetic studies: Issues of concern. Statist Med 2008;27:6547-69). Five additional quality assessment questions were asked that were specific to TPMT testing. Compliance with the different items was repor-	Authors' conclusion: "This meta-analysis suggests that individuals with both intermediate and absent TPMT activity have an increased risk of developing thiopurine-induced myelosuppression, compared with individuals with normal activity." "This study highlights that the increased risk of myelosuppression for intermediate-activity patients, while present, is low and should not preclude the use of thiopurine medications."

			a clinical reality.” Dose versus the standard: PM: 15%
ref. 51 - cytostat Evans WE et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.	3 IM+PM: E	A total of 23 children with excessive toxicity to thiopurines: 2x auto-immune diseases treated with azathioprine; 19x ALL treated with mercaptopurine; 1x ALL with thioguanine; 1x ALL with 6-MP and 6-TG during various periods. - The patients were found to be 6x PM, 9x IM and 8x NM. The frequency of 65.2% IM + PM within these toxic patients is higher than the expected frequency of 10% within the general population (S). - Toxicity. Haematological toxicity alone or in combination with other toxicities occurred in 21/23 (90%) of the patients. No significant differences between the three TPMT phenotypes were found for: - the number of weeks of therapy before toxicity occurred - the occurrence of various types of toxicity (haematopoietic toxicity, hepatotoxicity or other toxicity) - the period required for recovery from neutropenia and resumption of the treatment - the treatments required for recovery (blood transfusion, thrombocyte transfusion, hospital admission, antibiotics, G-CSF). - Following dose reduction of 6-MP or 6-TG, the patients tolerated the therapy without acute toxicity and 50-62% could be treated with a complete dose of their other chemotherapy. Median dose reduction: - NM: 8.3% (from median 350 to median 280 mg/m² per week) - IM: 66.7% (from median 525 to median 175 mg/m² per week) - PM: 90.8% (from median 350 to median 32 mg/m² per week) The initial doses, the reduced doses and the percentage reduction all varied between the three TPMT phenotypes (S). - 2/17 patients in remission experienced an exacerbation: 1x NM and 1x IM. N.B.: TPMT activity was determined by phenotyping and confirmed by genotyping for 6/6 PM (6x *3A/*3A), 3/9 IM (2x *1/*3A, 1x *1/*3C) and 6/8 NM. No TPMT mutation (*2, *3A, *3B or *3C) was found for 5/9 IM. One IM was not tested.	Authors' conclusion: “There is a significant (> six-fold) overrepresentation of TPMT deficiency or heterozygosity among patients developing dose-limiting hematopoietic toxicity from therapy containing thiopurines. However, with appropriate dose adjustments, TPMT-deficient and heterozygous patients can be treated with thiopurines, without acute dose-limiting toxicity.” Median maintenance dose versus NM: IM: 63% PM: 11%
ref. 52 - cytostat Relling MV et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.	4 [#]	A total of 180 children with ALL (161x NM, 17x IM, 2x PM) received 6-mercaptopurine 75 mg/m² per day + methotrexate 40 mg/m² per week i.v. or i.m. for 2.5 years. During the first year, the therapy is interrupted every six weeks for treatment with either high-dose methotrexate or teniposide + cytarabine. Dose reduction in the event of myelosuppression. PM: reduction in dose of 6-MP from 75 mg/m² per day to 10 mg/m² 3x per week. IM: reduction to dose resulting in leukocytes < 4x10⁹/L and neutrophils > 0.3x10⁹/L. - 6-TGN concentrations were inversely proportional to TPMT activity (S): NM: 417 ± 179 pmol/8x10⁸ RBC	Authors' conclusion: “Lowering doses of 6-mercaptopurine in TPMT heterozygotes and in deficient patients allowed administration of full protocol doses of other chemotherapy while maintaining high thioguanine nucleotide concen-

ref. 54, continuation		100x10⁹/L and leukocytes 1.5-4.0x10⁹/L. The dose was eventually maintained at 15-25 mg/m² per day (average 20.0 mg/m² per day). TPMT deficiency was confirmed (genotype *3A/*3C and very low TPMT activity). The patient is still in the first ALL remission six years after diagnosis. - For both patients on a reduced dose of 6-MP, the RBC 6-TGN concentration is several times higher than at 100% dose for normal patients. - In both patients, blood counts drop rapidly after administration of methotrexate (1 or 5 g/m² i.v. in 24 hours). For the first patient, this resulted in a further three episodes of pancytopenia with reduced dose of 6-MP, for which treatment was stopped temporarily. His methotrexate was reduced to 15 mg/m² per week. No adjustment of the treatment was required for the second patient. He did not experience this decrease without 6-MP. The authors postulate that inhibitors of <i>de novo</i> purine synthesis could increase the toxic effects of 6-TGN.	following HDMTX, a further reduction of 6MP 2 weeks prior to HDMTX in order to reduce intracellular 6TGN may ameliorate bone-marrow suppression (unpublished data)." Dose versus the standard dose: *3A/*3A: 4.4% *3A/*3C: 26.7%
ref. 55 - imm sup SmPC Imuran (azathioprine) 02-07-21.	0 IM: A PM: E	<u>Dose:</u> Patients with a congenital low or absent activity of thiopurine S-methyltransferase (TPMT) are at increased risk of severe azathioprine toxicity with conventional doses of azathioprine. These patients usually require substantial dose reduction. The optimum initial dose for patients with homozygous TPMT deficiency has not been determined. Most patients with heterozygous TPMT deficiency are able to tolerate the recommended doses of azathioprine, but dose reduction may be required for some. Tests are available for genotyping and phenotyping for TPMT. <u>Warning:</u> In rare cases, individuals have a congenital deficiency of the enzyme thiopurine S-methyltransferase (TPMT). They can be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid myelosuppression following initiation of azathioprine treatment. This problem can be exacerbated by simultaneous administration of medicines that inhibit TPMT, such as: olsalazine, mesalazine or sulphasalazine. A possible link has also been reported between reduced TPMT activity and secondary leukaemia and myelodysplastic syndrome in individuals who received 6-mercaptopurine (the active metabolite of azathioprine) in combination with other cytotoxic drugs. There are laboratories that offer tests for TPMT deficiency, but it has not been demonstrated that these tests can detect all patients at risk of severe toxicity. Therefore, it remains essential to monitor blood counts closely. <u>Pharmacology:</u> Patients with variants in both the NUDT15 and the TPMT enzyme tolerate thiopurines significantly less than patients with risk alleles of only one of these two genes. <u>Pharmacokinetics:</u> The activity of TPMT is inversely proportional to the concentration of thioguanine nucleotides from 6-mercaptopurine in red blood cells, with higher concentrations of thioguanine nucleotides resulting in greater reductions in the numbers of white blood cells and neutrophils. People with TPMT deficiency develop very high, cytotoxic concentrations of thioguanine nucleotides. The allele pattern of a patient can be determined by genotype testing. According to the current knowledge, three alleles –	

effect for PM was scored as if this concerned a case. This was indicated by placing the case code (2) behind the relevant score.

Risk group	Use of TPMT inhibitors (aminosalicylates: mesalazine, olsalazine or sulphasalazine, furosemide, acetylsalicylic acid) or xanthine oxidase inhibitors (allopurinol, febuxostat), use of inhibitors of <i>de novo</i> purine synthesis (methotrexate), NUDT15 IM or PM (frequent in East Asian patients) Note: results regarding the effect of the aminosalicylates are contradictory. Five studies clearly showed no <i>in vivo</i> drug interaction (Szumlanski CL et al. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9; Dewit O et al. Interaction between azathioprine and aminosalicylates: an <i>in vivo</i> study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85; Dilger K et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 2007;29:1-5; de Graaff P et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010;160:1083-91; Reinisch W et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59:752-9).
------------	---

Comments:

- Due to the large number of articles about TPMT and AZA/6-MP, a selection was made for the status report. The selection took place according to the following criteria:
For the period up to and including 2010:
 - clinical effects
 - genotyping
 - either studies involving more than 10 IM or more than 2 PM (before 2007) / or studies with more than 50 IM or more than 2 PM (after 2007)
 - either studies or case reports in which an alternative is suggested for treatment of IM and/or PM (lower dose or different drug) / or in which 6-TGN concentrations and doses are stated for NM and IM and/or PM / or in which the dose for IM was reduced to such an extent that there is no longer a difference in adverse events between NM and IM

Following this selection, there were twenty articles prior to 2007, to which the following three articles were added on the advice of Dr L.J.J. Derijks:

- Black AJ et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Annals of Internal Medicine 1998;129:716-8.
- Campbell S et al. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002;16:389-98.
- Gearry RB et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400.

For the period after 2010:

- clinical studies of patients with conditions other than auto-immune hepatitis, and not investigating genotype-guided therapy, were not included if the number of patients was lower than 600 (period from 2011 up to May 2015) or 750 (period from May 2015). These studies do not contribute sufficiently to the burden of proof.

The article "Lennard L et al. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol 2013;76:125-36." was not included, because this is a less expansive version of Lennard Br J Haematol 2015;169:228-40 and contains no additional relevant information. The article "Yang JJ et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015;33:1235-42. PubMed PMID: 25624441." was not included, because this is a less expansive version of Liu 2017 and contains no additional relevant information.

The article "Booth RA et al. Assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs. Evid Rep Technol Assess (Full Rep) 2010;196:1-282." was not included, because this contains a less expansive meta-analysis than Booth, 2011.

The article "Taha N et al. TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: first experience. Pulm Pharmacol Ther 2021;66:101988. PMID: 33406412" was not included, because the effect of genotyping was only investigated for TPMT and HLA-alleles increasing pancreatitis risk combined and comparison was only for the full cohorts (n = 49 +

33), not for only the azathioprine users (n = 37+26). Because the number of patients not started on azathioprine due to HLA allele positivity was 11-fold that for TPMT variant positivity and the number of patients started on reduced dose 1.4-fold, the study mainly investigated the effect of HLA genotyping. The article “Chang JY et al. Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020;18:2010-18.e2. PMID: 31446180” was not included, because the effect of genotyping was only investigated for NUDT15, CFO and TPMT together and the number of heterozygotes of these genes in the genotype-guided group was 15, 8 and 1 respectively, indicating that TPMT genotype hardly contributed to the results. In addition, initial azathioprine doses were not adjusted for variant allele carriers.

- during the period from 2011 up to May 2015, there were no studies that examined the link between the TPMT genotype and measures of outcome in patients with auto-immune hepatitis
- as the dose data for PM are limited, articles were also included in which a dose for PM was determined
- kinetic studies were only included if they contained mean doses corrected for 6-TGN concentrations per genotype group.

- Dose recommendations in reviews/articles

- Clinical Pharmacogenetics Implementation Consortium Guidelines (Relling et al., Clin Pharmacol Ther 2011;89:387-91, Clin Pharmacol Ther 2013;93:324-5 and Clin Pharmacol Ther 2019;105:1095-1105. PubMed PMID: 30447069):

CPIC defines TPMT IM and TPMT PM as we do (one or two no function alleles, respectively), but considers only *2, *3A, *3B, *3C, *4, *11, *14, *15, *23, and *29 to be no function alleles. CPIC considers the other alleles, including *5 through *10 and *12 to be alleles with uncertain function. CPIC groups combinations of one allele with uncertain function and one no function allele in the phenotype ‘possible IM’ instead of in the IM phenotype. In addition, CPIC groups combinations of two uncertain function alleles and combinations of one normal function and one uncertain function allele in the phenotype ‘indeterminate’.

CPIC indicates that TPMT PM are at very high risk for life-threatening myelosuppression, due to very high 6-TGN levels, if given conventional doses of 6-mercaptopurine (or azathioprine). In addition, CPIC indicates that despite having higher 6-TGN levels than NM, only about 30–60% of TPMT IM cannot tolerate full doses of 6-mercaptopurine or azathioprine (Relling 1999, Evans 2001, Stocco G et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-72 and Ford LT et al. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. J Clin Pathol 2010;63:288-95). CPIC indicates that good thiopurine tolerance in some IM may be because, although they have higher 6-TGN levels than NM, they have lower concentrations (and, thus, fewer toxic effects) of the methylmercaptopurine nucleotides (6-MMPN) than do NM, which may offset the toxic effects of having higher 6-TGN levels. Thus, there is less of a consensus over how to dose azathioprine and mercaptopurine in patients who are TPMT IM compared with those who are PM, although they are at a higher risk for toxicity compared with NM (Higgs 2010).

CPIC states that there is substantial evidence linking TPMT genotype with phenotypic variability. In addition, pre-emptive dose adjustments based on TPMT genotype have reduced thiopurine-induced adverse effects without compromising desired antitumor and immunosuppressive therapeutic effects in several clinical settings (Ford LT et al. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. J Clin Pathol 2010;63:288-95; Relling 1999; Schmiegelow K et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009;23:557-64; Schmiegelow K et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345-54; and Meggitt SJ et al. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006;367:839-46).

CPIC states that, if starting doses are already high (e.g., 75 mg/m² of 6-mercaptopurine), as is true in some ALL treatment regimens, lower than normal starting doses should be considered in TPMT IM (Stocco G et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-72; Lennard L et al. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18:328-34; Schmiegelow K et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009;23:557-64; and Schmiegelow K et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345-54) and markedly reduced doses (10-fold reduction) should be used in TPMT PM (Evans WE et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985-9). This approach has decreased the risk of acute toxicity without compromising relapse rate in ALL (Relling MV et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006;107:843-4).

Even at these markedly reduced dosages, erythrocyte 6-TGN concentrations in TPMT PM remain well above those tolerated and achieved by the majority of patients (who are TPMT NM (Ford LT et al. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. *J Clin Pathol* 2010;63:288-95; and Evans WE et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. *J Pediatr* 1991;119:985-9).

CPIC indicates that in some non-malignant conditions, alternative agents may be chosen for IM or PM rather than reduced doses of thiopurines; if thiopurines are used, full starting doses are recommended for NM, reduced doses (30-80% of target dose) in IM (Meggit SJ et al. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet* 2006;367:839-46; and Coenen 2015), and substantially reduced doses (or use of an alternative agent) in PM (Ford LT et al. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. *J Clin Pathol* 2010;63:288-95; and Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. *Gut* 2001;48: 591-2).

CPIC indicates that some of the clinical data upon which dosing recommendations are based rely on measures of TPMT phenotype rather than genotype; however, because TPMT genotype is strongly linked to TPMT phenotype (Schaeffeler E et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Whites and identification of novel TPMT variants. *Pharmacogenetics* 2004;14:407-17; Yates CR et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann Intern Med* 1997;126:608-14; Liu 2017; and Tamm R et al. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. *Clin Pharmacol Ther* 2017;101:684-95), these recommendations apply regardless of the method used to assess TPMT status.

CPIC classifies all recommendations as strong (i.e. “the evidence is high quality and the desirable effects clearly outweigh the undesirable effects”).

The therapeutic recommendations for 6-mercaptopurine and azathioprine are indicated below:

Dosing recommendations for 6-mercaptopurine and azathioprine by TPMT phenotype			
Phenotype	Therapeutic recommendation		Classification of recommendation
	6-mercaptopurine	azathioprine	
IM (one no function allele: *2, *3A, *3B, *3C, *4, *11, *14, *15, *23, or *29) or possible IM (one allele with uncertain function (allele other than *1, *2, *3A, *3B, *3C, *4, *11, *14, *15, *23, or *29) and one no function allele)	Start with reduced starting doses (30-80% of normal dose) if normal starting dose ^a is ≥ 75 mg/m ² /day or ≥ 1.5 mg/kg/day (e.g., start at 22.5–60 mg/m ² /day or 0.45–1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents ^b . If normal starting dose is already < 75 mg/m ² /day or < 1.5 mg/kg/day, dose reduction may not be recommended.	Start with reduced starting doses (30-80% of normal dose) if normal starting dose ^a is 2-3 mg/kg/day (e.g., 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment ^c .	Strong ^d
PM (two no function alleles: *2, *3A, *3B, *3C, *4, *11, *14, *15, *23, or *29)	For malignancy, start with drastically reduced doses (reduce daily dose ^a by 10-fold and reduce frequency to thrice weekly instead of daily (e.g., 10 mg/m ² /day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose ^a by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific	Strong ^d

	dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy ^e .	guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment ^f .	
--	--	---	--

^a Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolisers.

^b Ford LT et al. J Clin Pathol 2010;63:288-95; Stocco G et al. Clin Pharmacol Ther 2009;85:164-72; Lennard L et al. Ther Drug Monit 1996;18:328-34; Schmiegelow K et al. Leukemia 2009;23:557-64; Schmiegelow K et al. Leukemia 2010;24:345-54; Relling MV et al. Blood 2006;107:843-4; Sandborn WJ. Gut 2001;48:591-2; Lichtenstein GR et al. Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87; Krynetski EY et al. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998;63:11-6.

^c Ford LT et al. J Clin Pathol 2010;63:288-95; Sandborn WJ. Gut 2001;48:591-2; Lichtenstein GR et al. Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87; Krynetski EY et al. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998;63:11-6.

^d The classification strong indicates that the evidence is high quality and the desirable effects clearly outweigh the undesirable effects.

^e Ford LT et al. J Clin Pathol 2010;63:288-95; Evans WE et al. J Pediatr 1991;119:985-9; Sandborn WJ. Gut 2001;48:591-2; Lichtenstein GR et al. Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87.

^f Meggitt SJ et al. Lancet 2006;367:839-46; Sandborn WJ. Gut 2001;48:591-2; Anstey AV et al. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:1123-32; Lichtenstein GR et al. Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87; Kaskas 2003.

Recommendations for patients having also a NUDT15 variant

CPIC states that there have been reports of patients with intermediate metaboliser status for both TPMT and NUDT15 (i.e., compound intermediate metabolisers), and that there was a trend for a lower thiopurine tolerance in these individuals compared with intermediate metabolisers for only TPMT or NUDT15. However, CPIC indicates that the evidence for a different starting dose recommendation for the compound intermediate metabolisers remains limited.

The therapeutic recommendations for patients having also a NUDT15 variant are indicated below:

Dosing recommendations for 6-mercaptopurine and azathioprine for patients with a genetically reduced activity for both TPMT and NUDT15		
TPMT phenotype	NUDT15 phenotype	Therapeutic recommendation
IM	IM	Consider dose reduction ^a . See TPMT IM and NUDT15 IM recommendation ^b .
IM	PM	Dose reduction recommended ^a . See NUDT15 PM recommendation.
PM	IM	Dose reduction recommended ^a . See TPMT PM recommendation.
PM	PM	Dose reduction recommended ^a . See TPMT PM recommendation.

^a Whether a dose reduction is recommended from the starting dose depends on the level of the standard starting dose; for example, if the standard starting dose of mercaptopurine is 75 mg/m²/day or higher, then a lower starting dose may be considered in intermediate metabolisers and would be recommended in poor metabolisers, whereas if the starting dose is 50 mg/m²/day or lower, a reduced starting dose may not be necessary in intermediate metabolisers.

^b For patients who are intermediate metabolisers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolisers with respect to one gene (TPMT or NUDT15).

As evidence linking TPMT genotype with 6-mercaptopurine and/or azathioprine phenotype, CPIC mentions 128 articles. 104 of these articles were not included in our risk analysis. 13 articles were not included in our risk analysis because they concerned *in vitro* or preclinical (mouse) studies. The other not included studies also did not fulfil our inclusion criteria (see the first item under Comments). In addition, our risk analysis includes 22 articles not included by CPIC of which 3 were recent (i.e. published after the last CPIC search) (Fan 2019, Choi 2019, Eriksen 2017, Van Moorsel 2017, Kim 2012, Newman 2011, the systematic review (PM) and meta-analysis (IM) Higgs 2010, Hindorf 2010, Sheffield 2009, Ansari 2008, Gardiner 2006, Moloney 2006, Jun 2005, Kurzawski Ther Drug Monitor 2005, Kurzawski Transplant Int 2005, Fabre 2004, Gilissen 2004, Gearry 2003, Schaeffeler 2003, Campbell 2002, Langley 2002, and

Pandy 2002). Instead of some of these articles, CPIC included other articles by the same author or group. CPIC indicates that the included *in vitro* studies provide a high level of evidence for mercaptopurine catabolism to methylmercaptopurine being absent in human erythrocytes, lymphocytes, liver, and kidneys from TPMT PM (4 studies), for the mechanisms of functional inactivation for TPMT *2, *3A, *3B, *3C, *4 demonstrated by expression of specific variant alleles (3 studies), for heterologous expression of TPMT catabolizing mercaptopurine to methylmercaptopurine, and TIMP (the 6-TGN precursor thioinosine monophosphate) to methylTIMP (2 studies), and for a higher sensitivity of TPMT knock-down cells to mercaptopurine in some cases compared to wild type (1 study). One *in vitro* study provided a low level of evidence that TPMT deficiency could lead to chronic exposure to thiopurine and could be linked to development of brain cancer (astrocytomas). CPIC indicates that the preclinical studies provide a high level of evidence for TPMT+/+ mice having higher survival with high doses of mercaptopurine but TPMT-/- mice having improved survival with lower doses (1 study), and for TPMT knock-out mice having more morbidity and mortality but better ALL efficacy from mercaptopurine than wild type mice; heterozygotes were at intermediate risk (2 studies), CPIC indicates that clinical studies provide a high level of evidence for increased risk of myelosuppression in TPMT IM receiving normal doses of mercaptopurine or azathioprine (43 references including Black 1998, McLeod 1999, Relling 1999, Colombel 2000, Evans 2001, Zelinkova 2006, the meta-analysis of Booth 2011, Lee 2013, Belen 2014, and Kim 2014), for TPMT status to be associated with dose reduction or cessation of therapy of azathioprine or mercaptopurine (17 references, including Evans 2001, Kaskas 2003, Lee 2013, Kim 2014, Lennard Br J Haematol 2015;169:228-40, and Liu 2017), for personalized dose for TPMT variant genotypes being significantly associated with decreased hematologic adverse drug reaction risk and decreased 6-TGN levels compared with standard doses (Coenen 2015), for TPMT wild-type patients with ALL having higher risk of relapse than those with at least one variant TPMT allele, particularly in regimens that are primarily antimetabolite-based, and wild-type patients with IBD having higher risk of treatment failure (4 references, including Ansari 2002), for TPMT PM having life-threatening toxicity (myelosuppression) from normal doses of mercaptopurine and azathioprine; toxicity can be minimized with substantially decreased doses (14 references, including Black 1998, McLeod 1999, Relling 1999, Colombel 2000, Kaskas 2003, and Zelinkova 2006), for increased risk of leukopenia in TPMT IM and PM receiving thiopurines for treatment of chronic inflammatory diseases (the meta-analysis of Booth 2011), for higher level of residual leukemia in TPMT NM than in IM/PM with ALL after 10 days of fixed-dose thiopurine but not in absence of thiopurines (Stanulla 2005), for no increase in acute toxicity in IM compared to NM with ALL who received mercaptopurine doses adjusted downward for TPMT defective patients (3 references, including Evans 2001), for TPMT genotyping to be useful in predicting myelosuppression from azathioprine in transplant recipients (5 references, none of which included in our risk analysis), and for no change in treatment efficacy for IBD patients who receive azathioprine based on TPMT status or thioguanine concentration (1 reference that is not included in our risk analysis). In addition, CPIC reports a high level of evidence that TPMT genotype correlates with TPMT activity measured by biochemical assay (variant genotypes have lower activity in general than *1/*1), but activity cannot be explained by genotype alone because the *1/*1 and variant (heterozygote) activities overlap (17 references, including Relling 1999, Ansari 2002, the meta-analysis of Booth 2011, Demlova 2014, and Liu 2017), and that TPMT variant genotype is associated with increased TGN levels and/or lower methylmercaptopurine nucleotide levels (8 references, including Kim 2014). CPIC reports a moderate level of evidence that *3C variant is associated with alopecia in patients with autoimmune disease (i.e. inflammatory bowel disease and lupus) (2 references, including Kim 2014), that TPMT variant genotype is NOT associated with greater likelihood of event free survival, but studies that adjust dose based on TPMT status or tolerance may be unlikely to find such associations (6 references, including Levinsen 2014, Lennard Br J Haematol 2015;169:228-40, and Lennard Br J Haematol 2015;170:550-8), that there is no change in relapse risk for IM with ALL who receive mercaptopurine doses adjusted downward for TPMT defective patients (2 references, both not included in our risk analysis), that risk of secondary leukemia in those with low TPMT activity and in those with high thiopurine active metabolites is increased (7 references, including Levinsen 2014), that TPMT genotyping is useful in predicting myelosuppression and likelihood of clinical response to azathioprine/mercaptopurine in IBD (11 references, including Zelinkova 2006 and Gardiner 2008), that TPMT genotyping is useful in predicting myelosuppression and likelihood of clinical response to azathioprine in Crohn's disease (5 references, including Colombel 2000 and Gardiner 2008), that TPMT genotype-based dosing reduced toxicity while maintaining drug efficacy in trial of azathioprine for moderate-severe atopic eczema (1 reference, published before 2010 and not included in our risk analysis), that TPMT genotyping is useful in predicting myelosuppression from azathioprine in rheumatoid arthritis (4 references, none of which included in our risk analysis), and that risk of hepatotoxicity to mercaptopurine in patients with TPMT wild-type genotype and/or higher mercaptopurine metabolites (6-MMPN (6-methylmercaptopurine nucleotides)) is increased (8 references, none of which included in our risk analysis). CPIC reports a weak level of evidence that TPMT variant genotype is associated with incidence of gastrointestinal adverse drug reactions (4 references, of which none included in our risk analysis), that TPMT status is associated with development of secondary cancer (5 references, including Levinsen 2014 and Lennard Br J Haematol 2015;169:228-40), and that the VNTR (variable number of tandem repeats) region in the TPMT promoter correlates with TPMT expression (not

statistically significant) (1 reference that is not included in our risk analysis). CPIC also reports a weak level of evidence that TPMT status is associated with development of secondary cancer based on 7 references, none of which are included in our risk analysis, but this seems to be a mistake, because this outcome is reported with other references directly above and not all of the 7 references mentioned concern cancer patients.

On 7-7-2023, there was not a more recent version of the recommendations present on the CPIC-site.

- Review Smith et al. (Pharmacogenomics 2010;11:421-37): recommendation is to treat PM with 5-8% of the azathioprine dose used for NM and to treat IM with 50-60% of the dose used for NM.
- Schmiegelow et al. (Leukemia 2009;23:557-64): Due to their higher risk of myelosuppression and supposed risk of secondary malignant tumours, the Scandinavian Association for Paediatric Haematology and Oncology (NOPHO) has, since 2001, adjusted the initial dose of mercaptopurine according to the TPMT genotype in all its ALL protocols (IM: 66.7% of the dose for NM (75 mg/m²), PM: 13.3% of the dose for NM). The dose is then adjusted according to the leukocyte count. It is not yet known whether this strategy affects the frequency of relapse of ALL for IM and PM. The old protocol found a lower risk of relapse of ALL for patients with low TPMT activity compared to patients with normal TPMT activity (7% versus 18%), but no improved survival, possibly due to a higher frequency of secondary tumours in this patient group.
- Review Wang and Weinshilboum (Oncogene 2006;25:1629-1638): In order to avoid toxicity, homozygous polymorphic patients should be treated with 1/10th to 1/15th of the standard dose of thiopurine and even then they require careful monitoring.

- Cost-effectiveness:

- van der Wouden CH et al. Cost-effectiveness of pharmacogenomics-guided prescribing to prevent gene-drug-related deaths: a decision-analytic model. Front Pharmacol 2022;13:918493. PMID: 36120299.
The costs per gene-drug-related death averted by genotype-guided treatment, was calculated for 148,128 Dutch patients starting one of seven drugs (azathioprine, 6-mercaptopurine, capecitabine, clopidogrel, systemic fluorouracil, irinotecan or tioguanine). The number of azathioprine initiators was 6,979, the number of mercaptopurine initiators 2,177. Genotype-guided treatment was according to the KNMP Pharmacogenetics Working Group recommendations. For PM, it was assumed that the recommendation for a dose decrease was followed, not the recommendation for an alternative drug. For azathioprine and mercaptopurine, the costs per death averted by TPMT genotyping and TPMT-guided therapy were € 374,411 and € 160,309 respectively. With a threshold of additional costs of € 20,000-60,000 per quality-adjusted life year (QALY) gained, this would be cost-effective if patients lived afterwards for 6-19 or 3-8 years with optimal quality of life, respectively.

Testing of CYP2C19, DPYD, TPMT or UGT1A1 for start of clopidogrel, capecitabine, systemic fluorouracil, azathioprine, mercaptopurine, tioguanine or irinotecan was cost-effective (additional costs of € 51,000 per prevented gene-drug-related death).

Costs were calculated over a period of 1 year and from a health care perspective. Only costs of genetic tests, health care professional interpretation, and drugs were included in the calculation. For the 6979 azathioprine initiators, TPMT-guided treatment was calculated to prevent 2.3 gene-drug-related deaths in the first year of treatment (decrease from 15.8 to 13.5 deaths) against additional costs of € 374,411 per prevented death. For the 2177 mercaptopurine initiators, TPMT-guided treatment was calculated to prevent 0.7 gene-drug-related deaths in the first year of treatment (decrease from 4.9 to 4.2 deaths) against additional costs of € 106,309 per prevented death. Costs for azathioprine were € 0.34 per 75 mg tablet and € 0.19 per 50 mg tablet, costs for mercaptopurine were € 2.68 per 50 mg tablet and € 16.35 per dose of 15 mg/ml solution, costs for pharmacist time were € 12.11 per 18 minutes, costs for physician time were € 4.28 per 6 minutes, and TPMT genotyping costs were € 132. The risk of gene-drug-related death was derived from literature review, the incidence of drug initiation from Dutch prescription data, and the predicted phenotype category frequencies from a Dutch sample of 1,023 individuals.

- Zeng D et al. Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data. Ann Transl Med 2021;9:1138. PMID: 34430579.
For azathioprine-treated Chinese patients with inflammatory bowel disease, prevention of severe thiopurine-induced leukopenia by TPMT-guided treatment was calculated to be both better and cheaper compared to not-genotype guided treatment. TPMT-guided treatment saved €73.9 per patient and provided an additional 0.00376 quality-adjusted life years (QALYs) per patient. TPMT-guided treatment consisted of normally dosed azathioprine treatment for NM patients, 50% of the normal azathioprine dose for IM patients, and an alternative drug (TNF- α inhibitors or methotrexate) for PM patients. In this Chinese patient group, TPMT- and NUDT15-guided treatment was both better and cheaper than TPMT-guided treatment, saving an additional \$25.15 per patient and providing an additional 0.00406 quality-adjusted life years (QALYs) per patient.

Therapeutic drug monitoring reduced the cost and increased the QALY even further.

Cost-effectiveness was calculated over a period of 1 year (because most severe cases of azathioprine-induced myelotoxicity occur within 1 year after initiation of treatment) and from the Chinese health care perspective. Only direct medical costs (costs of the genetic test and costs of treatment) were included in

the calculation. The mean estimated costs of the not-genotype-guided and TPMT-guided treatments for 1 year were € 721.82/patient and € 647.92/patient, respectively. The total of QALYs gained in the not-genotype-guided and TPMT-guided treatments for 1 year were 0.87873 and 0.88249, respectively. Cost of standard dose azathioprine was \$243/year (including prescription and laboratory test fees (i.e., complete blood count and blood chemistry for liver enzymes)), cost of 50%-reduced-dose azathioprine was \$182/year (including prescription and laboratory test fees (i.e., complete blood count and blood chemistry for liver enzymes)), cost of methotrexate was \$211/year (including prescription and laboratory test fees (i.e., complete blood count and blood chemistry for liver enzymes)), cost of TNF- α inhibitor use (including office visits, and hospitalisations for infusion) was \$20,457/year, cost of treatment of azathioprine-induced severe myelotoxicity was \$363, TPMT genotyping cost was \$51.5. Prevalence of TPMT genotypes, efficacy of genotype screening, and the probability of severe myelotoxicity (absolute neutrophil count $<0.5 \times 10^9/L$ or pancytopenia needing hospital admission for treatment) were retrospectively derived from 391 patients with inflammatory bowel disease. The frequency of TPMT PM was 0.037% in this Chinese cohort (corresponding to an inactive allele frequency of approximately 1.9%). The frequency of NUDT15 PM was 1.6% (corresponding to an inactive allele frequency of approximately 12.6%).

- Sluiter RL et al. Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease. *J Crohns Colitis* 2019;13:838-45. PMID: 30698675.
Cost-effectiveness of TPMT-guided thiopurine treatment for Dutch patients with inflammatory bowel disease was calculated based on data from a randomised controlled trial with 381 patients in the TPMT-guided treatment group and 347 patients in the not-genotype guided treatment group. TPMT-guided thiopurine treatment was calculated to be both better and cheaper compared to not-genotype guided treatment. TPMT-guided treatment saved €52 per patient and provided an additional 0.001 quality-adjusted life years (QALYs) per patient. However, confidence intervals were wide and cost-saving and increase in QALYs both not significant. A probability of 56% was found for TPMT-guided treatment to be cost-effective at a willingness-to-pay threshold of € 20,000. The authors conclude that TPMT-guided thiopurine treatment in patients with inflammatory bowel disease reduced the risk of adverse drug reactions among patients carrying a TPMT variant, without increasing overall healthcare costs and resulting in comparable quality of life, as compared to not-genotype guided treatment. TPMT-guided treatment recommendation consisted of normally dosed thiopurine treatment for NM patients (2-2.5 mg/kg azathioprine per day or 1-1.5 mg/kg 6-mercaptopurine per day), 50% of the normal thiopurine dose for IM patients, and 0-10% of the normal thiopurine dose for PM patients. Doses could be changed or treatment stopped in case of adverse events. Genotyping was for *2, *3A and *3C.
Cost-effectiveness was calculated over a period of 20 weeks (because the majority of haematological adverse events occur within 4 months of treatment initiation) and from a societal perspective. Medical costs and productivity loss (disease-related absence from work) were included in the calculation. Cost-effectiveness was calculated by non-parametric bootstrapping with 1000 replications. The mean estimated cost of the not-genotype-guided and TPMT-guided treatments was € 2232/patient and € 2181/patient, respectively. The total of QALYs gained in the not-genotype-guided and TPMT-guided treatments were 0.301 and 0.302, respectively. Cost of azathioprine was € 0.37 per daily defined dose (DDD), cost of mercaptopurine was € 2.54 per unit dose, cost of productivity loss was € 34.75 per missed working hour, genotyping cost was €150.
The percentage of patients treated with biologicals was lower in the TPMT-guided treatment group (3.7%) than in the control group (7.2%). Cost of medication use was lower in the TPMT-guided treatment group (€ 302) than in the control group (€ 387).
In 57% of the replications, TPMT-guided treatment resulted in QALYs gained, of which 56% (32% of total replications) also resulted in lower costs.
Similar results were obtained with genotyping cost of € 100.
- Zarca K et al. Modeling the outcome of systematic TPMT genotyping or phenotyping before azathioprine prescription: a cost-effectiveness analysis. *Mol Diagn Ther* 2019;23:429-38. PubMed PMID: 30963516.
The additional costs per case of severe myelosuppression averted, were calculated for French adult patients with IBD for whom azathioprine was considered suitable as first-line monotherapy. Severe myelosuppression was defined as an absolute neutrophil count below $0.5 \times 10^9/L$, a level associated with a significant risk of infection which should be managed on an inpatient basis, or as pancytopenia requiring hospitalization. Screening for TPMT deficiency, with either genotyping or phenotyping, was compared to the absence of screening. The additional costs per case of severe myelotoxicity averted were € 2,602 in the phenotyping strategy, and € 11,244 in the genotyping strategy compared to the no screening strategy. At prevalence rates of severe myelotoxicity $> 1\%$, phenotyping was both cheaper and better than genotyping and no screening strategies. The probability of phenotyping to be cost-effective was 90% if the decision-maker is willing to pay more than € 7000 (median cost for a hospital stay for toxic myelosuppression) for an additional averted episode of severe myelotoxicity. However, because the additional costs for averting one case of severe myelotoxicity were considerably larger than the median costs of treating one case of severe myelotoxicity, genotyping was unlikely to be cost-effective.
Genetic screening was for TPMT*2, *3A, *3B and *3C. Patients with TPMT deficiency (TPMT PM or very

low TPMT activity) were given alternative therapy (anti-TNF- α or a reduced (10%) dose of azathioprine). TPMT IM received normal azathioprine therapy.

Cost-effectiveness was calculated over a period of 1 year (because the vast majority of azathioprine-related severe myelotoxicities occur within 1 year of the initiation of treatment) and from the French health care payer perspective. Only direct medical costs (costs of the diagnostic test and costs of treatment) were included in the calculation. The mean estimated costs of the no screening, phenotyping and genotyping strategies for 1 year were € 409/patient, € 427/patient and € 476/patient, respectively. Phenotyping resulted in 0.007 severe myelosuppressions avoided over a year versus 0.006 for genotyping. Costs for azathioprine (including monthly cell blood counts and liver tests) were € 300/year, costs for TNF- α inhibitors (including office visits, and hospitalisations for infusion) were € 4200/year, TPMT genotyping costs were € 110 (corresponding to the reimbursement by the health care system), and TPMT enzymatic activity assay costs were € 67 (corresponding to the reimbursement by the health care system). Prevalence rates of TPMT genotypes/phenotypes, sensitivity and specificity of TPMT testing, and incidence of severe myelosuppression from previous reports were used. From these data, the authors selected the most frequently reported values: a prevalence of TPMT PM of 0.6% and a prevalence of low TPMT activity in the general population of 0.7%, a sensitivity of genotyping of 60% and a sensitivity of phenotyping of 70%, a specificity of genotyping of 99.6% and a specificity of phenotyping of 99.7%, and a probability of a severe myelotoxicity of 1%. The authors assumed that 100% of those with low TPMT activity would develop severe myelosuppression if treated with full-dose azathioprine. They hypothesized that azathioprine treatment was discontinued and replaced by anti-TNF- α or reduced doses of azathioprine if patients developed severe bone marrow toxicity. Furthermore, they assumed that the only side effect of azathioprine was myelotoxicity.

- Plumpton CO et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. *Pharmacoeconomics* 2016;34:771-93. PubMed PMID: 26984520. The authors performed a systematic literature review of economic evaluations of pharmacogenetic tests of TPMT prior to prescription of 6-mercaptopurine or azathioprine. The authors conclude that economic evidence was inconclusive, with considerable variation in results across several high-quality studies indicating that genotyping was not cost effective. The authors mentioned that there was only one notable trial of TPMT genotyping preceding start of 6-mercaptopurine or azathioprine (Newman 2011). Eleven economic evaluations were retrieved: four conducted in Canada (Donnan 2011, Marra 2002, Sayani FA et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. *Can J Gastroenterol* 2005;19: 147-51, and Tavadia 2000), two conducted in the USA (Dubinsky 2005 and Hagaman 2010), two conducted in the UK (Thompson 2014 and Winter 2004), one conducted in Europe (other than the UK) (Van den Akker-van Marle 2006), one in New Zealand (Priest 2006), and one in Korea (Oh KT et al. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. *Rheumatology* 2004;43:156-63). Four studies were cost-minimisation or cost-benefit analyses (Donnan 2011, Dubinsky 2005, Sayani 2005, and Tavadia 2000). Four studies were cost-effectiveness analyses reporting costs per life-year gained (van den Akker-van Marle 2006 and Winter 2004) or events averted (Marra 2002 and Oh 2004). Three evaluations were cost-utility analyses (Thompson 2014, Hagaman 2010, and Priest 2006). Costs were calculated from the perspective of the healthcare provider in four studies (Thompson 2014, Donnan 2011, Sayani 2005, and Winter 2004) and (also) from a societal perspective in four (van den Akker-van Marle 2006, Oh 2004, Winter 2004, and Marra 2002). Eight evaluations (Donnan 2011, Hagaman 2010, Priest 2006, van den Akker-van Marle 2006, Dubinsky 2005, Oh 2004, Winter 2004, and Marra 2002) were based on economic models, two were conducted alongside prospective randomised studies (Thompson 2014 and Sayani 2005) and one analysis was based on a case report (Tavadia 2000). The quality of reporting in the economic evaluations was high for 7 of the 11 studies (Thompson 2014, Donnan 2011, Priest 2006, Dubinsky 2005, Sayani 2005, Oh 2004, and Marra 2002). High quality was defined as reporting of more than 85% of items on a 24-item checklist for economic health evaluations. The perspective was unclear in Tavadia 2000. Van den Akker-van Marle 2006 did not state explicitly the modelling approach. Van den Akker-van Marle 2006 and Winter 2004 did not mention explicitly a time horizon, although a lifetime time horizon could be assumed for these studies. Winter 2004 did not mention sensitivity analysis explicitly. Four studies stated that the evidence supporting the effectiveness of pharmacogenetics testing was retrieved from literature searches (Donnan 2011, Dubinsky 2005, Oh 2004, and Marra 2002), two mentioned retrospective genotyping as source (Priest 2006 and Winter 2004), one mentioned cohort studies (Hagaman 2010), and two were vague about the sources (Tavadia 2000, Van den Akker-van Marle 2006). Two studies used random controlled trial evidence of the effectiveness of pharmacogenetics testing (Thompson 2014 and Sayani 2005).

Studies had mixed results across different settings and disease areas. While four high-quality studies found testing to be cost saving or to be both cost saving and better than standard dosing (Donnan 2011, Dubinsky 2005, Oh 2004, and Marra 2002), evaluations based on random controlled trial evidence indicated that testing was either not cost effective (Sayani 2005) or was less costly and less effective (Thompson 2014). Phenotype testing was less expensive (Donnan 2011) or more cost effective (Priest 2006)

than genotyping, and this is more in line with practice (Thompson 2014). The authors state that the FDA recommends genetic testing before prescribing azathioprine, whilst the Japanese PMDA (Pharmaceuticals and Medical Devices Agency) and Health Canada (Sante Canada; HCSC) both note that there are actionable genetic variants that determine efficacy, dosage or toxicity.

- Thompson et al. (Value Health 2014;17:22-33. PubMed PMID: 24438714): The authors use a randomised study in which 167 patients with auto-immune diseases with TPMT genotype known before start of azathioprine were compared to 166 patients for who this was not the case (Newman 2011). The data from this study and costs of £ 20 per genotyping test did not result in significantly reduced costs for genotype-based treatment (- £ 421; 95% CI: -925 – 90) and the quality-adjusted life-years gained decreased very little and non-significantly (-0.008 years over a follow-up period of 4 months; 95% CI: -0.017-0.0002). At a sum of £ 20,000 per life-year gained, the net benefits (amount per life-year gained x difference in life-years gained minus the difference in costs) were not significantly positive (£ 257; 95% CI: -426 – 933). At TPMT test costs of £ 350, equivalent to a “medium genetic test” from a 2006 consultation for a national tariff for genetic tests, genotyping would have only a 47% chance of being cost-effective at a threshold of £ 20,000 per life-year gained. If the test instead costs only £ 150, the price of a “simple genetic test”, then the probability of TPMT genotyping being cost-effective would rise to 71%. With Newman 2011 not demonstrating a better overall outcome for genotype-guided versus non-genotype-guided therapy, this probability of cost-effectiveness is due to the lower medication costs for IM receiving reduced azathioprine dose.

Doctors were advised to use an initial dose of 2-3 mg/kg per day for NM. A reduced initial dose was recommended for IM (for example 25-50 mg/day), followed by titration of the maintenance dose. PM were not present in the group for which the genotype was known at the start of treatment. The primary endpoint of the study was withdrawal of azathioprine due to adverse events in the first four months of treatment. There was no difference in the primary endpoint between the groups with genotype-based and non-genotype-based treatment. There was also no difference in the primary endpoint between NM and IM in the group with genotype-based treatment. In this group, the initial dose for IM was lower than for NM, but there was no difference in the dose after 4 months. However, the initial dose for NM with genotype-based treatment was equal to the initial dose for the non-genotype-based treatment and 2-3x lower than the recommended initial treatment. There was little difference in the use of healthcare services between the groups with genotype-based and non-genotype-based treatment. The number of patients with more than 1 hospital admission was lower in the genotyping group (0.6% versus 3.6%). At £ 20 per genotyping test, this resulted in lower, calculated costs for genotype-based treatment (£ 1,683.40 versus £ 1,966.78). However, the difference in costs was not significant after correction (- £ 421; 95% CI: -925 – 90). Quality-adjusted life-years (QALYs) were calculated from the health-related quality of life measured before and after treatment. The number of QALYs increased less in the genotyping group (0.233 versus 0.243). However, the difference was not significant after correction (-0.008; 95% CI: -0.017 – 0.0002). The probability of cost-effectiveness decreased as the costs per life-year gained increased and as the costs for the genotyping test increased.

- Donnan JR et al. (Pediatr Blood Cancer 2011;57:231-9): Genotyping for TPMT was not cost-effective in the treatment of patients with acute lymphoblastic leukaemia with mercaptopurine. The costs increased with genotyping by 277 Canadian dollars (95% CI: 112-442), whilst the overall survival did not increase in the first three months of the treatment. Cost-effectiveness was determined in comparison to a standard treatment, where the initial dose was calculated according to weight. However, if myelosuppression occurred, the genotype was determined and the desired dose reduction was determined accordingly. The genotype-based treatment was based on the standard treatment for NM and IM (dose adjustment only in the case of myelosuppression). A reduction of the initial dose was only assumed for PM. The difference between genotype-based and non-genotype-based treatment is therefore small.

The parameters used in the model were obtained from the literature or based on expert opinion.

Parameters included genotyping costs of \$ 460 per test, a 3% incidence of myelosuppression, hospital admission in 15% of the cases of myelosuppression and a mortality risk of 2.9% following hospital admission for febrile neutropenia and 0% following other forms of myelosuppression. It was assumed that 30% of the cases of myelosuppression were prevented by dose reduction in IM and PM. Considering the high percentage of myelosuppression in PM at initial dose, this is probably an underestimate for PM. Genotyping would be cost-effective at genotyping costs below \$ 12 per test.

The authors reported that the Children's Oncology Group in 2008 recommended an initial dose of 60% for IM and less than 10% for PM. The Children's Oncology Group recommended no genotyping before start of treatment, but only after occurrence of adverse events in order to determine the desired dose reduction.

- Hagaman et al. (Lung 2010;188:125-32): The authors estimate that TPMT genotyping before start of thiopurine therapy in patients with pulmonary fibrosis reduces the absolute risk of developing azathioprine-related bone marrow toxicity by approximately 2%. As approximately 16% of the patients with azathioprine-related leukopenia require hospital admission, this means that approximately 50 patients need to be screened in order to prevent one case of leukopenia and approximately 313 patients need to be screened to prevent one hospital admission. As TPMT genotyping is relatively cheap, the

prevention of one case of complicated leukopenia should easily outweigh the costs of the tests.

- Review Compagni et al. (Int J Technol Assess Health Care 2008;24:294-302): The authors concluded that TPMT genotyping is not cost-effective at a price of € 68 for a genotyping assay. At this price, the costs of a case of neutropenia amount to € 2,116 and the costs of preventing a case of neutropenia amount to € 5,300.
- Review Teml et al. (Clin Pharmacokinet 2007;46:187-208): Dubinsky 2005 found that TPMT genotyping before start of treatment reduces both the time to response for azathioprine (19.1 versus 22.4 weeks) and the treatment costs (\$ 3861 versus \$ 7142) in patients with Crohn's disease and ulcerative colitis (Dubinsky MC et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100:2239-47). Similar results were found by Winter 2004 and Priest 2006 (Winter J et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:593-9, and Priest VL et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006;24:767-81). Cost-effectiveness was also found in studies that examined the effect of genotyping for TPMT with thiopurine treatment for ALL (Van den Akker-van Marle 2006) or arthritic or dermatological conditions (Marra 2002 and Tavadia 2000) (van den Akker-van Marle ME et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006;7:783-92, Marra CA et al. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-12, and Tavadia SM et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42:628-32). One study (29 patients with Crohn's disease or ulcerative colitis) found higher costs (primarily due to the costs of the genotyping assay) if genotyping was performed, but there was only one patient in this small study who developed TPMT-related toxicity. A large, prospective study into cost-effectiveness of TPMT genotyping in patients with Crohn's disease or ulcerative colitis was started in 2007.

Date of literature search: 12 May 2023.

	Phenotype	Code	Gene-drug interaction	Action	Date
KNMP Pharmacogenetics Working Group decision	PM	4F	Yes	Yes	25 September 2023
	IM	4E	Yes	Yes	

N.B. Some articles refer to a lower efficacy for NM with relatively high TPMT activity (called "high NM" in the risk analysis). This could correspond to a UM, but has not been defined (yet) for TPMT. The working group has decided to only provide therapeutic recommendations based on genotype (i.e. for IM and PM).

Mechanism:

Lower metabolic activity of TPMT leads to increased intracellular concentrations of thioguanine nucleotides, the active metabolites of azathioprine and mercaptopurine. This increases the risk of adverse events such as myelosuppression.

Azathioprine and mercaptopurine are inactive pro-drugs, which are converted to the active metabolites – thioguanine nucleotides – in the body via several steps. Azathioprine is converted in the body to mercaptopurine and nitro-methyl imidazole. 6-Mercaptopurine is then converted to thioguanine nucleotides in three steps. The first of these steps is catalysed by the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT).

Two catabolic routes reduce mercaptopurine bio-availability for thioguanine nucleotide formation. Thiopurine methyltransferase (TPMT) catalyses S-methylation of both mercaptopurine and the metabolites formed by HPRT (6-mercaptopurine nucleotides or 6-thio-inosine nucleotides). The methylated 6-thio-inosine nucleotides contribute to the anti-proliferative properties of the thiopurines, probably through inhibition of *de novo* purine synthesis. High concentrations of methylated 6-thio-inosine nucleotides are also associated with a higher risk of hepatotoxicity. In addition to this, mercaptopurine is oxidised to the inactive 6-thiouric acid by the enzyme xanthine oxidase (XO), which occurs primarily in the liver and intestines.

Clinical Implication Score:

Table 1: Definitions of the available Clinical Implication Scores

Potentially beneficial	PGx testing for this gene-drug pair is potentially beneficial. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the DPWG recommends adhering to the gene-drug guideline	0-2 +
Beneficial	PGx testing for this gene-drug pair is beneficial. It is advised to consider	3-5 +

	genotyping the patient before (or directly after) drug therapy has been initiated to guide drug and dose selection	
Essential	PGx testing for this gene-drug pair is essential for drug safety or efficacy. Genotyping must be performed before drug therapy has been initiated to guide drug and dose selection	6-10 +

Table 2: Criteria on which the attribution of Clinical Implication Score is based

Clinical Implication Score Criteria	Possible Score	Given Score
Clinical effect associated with gene-drug interaction (drug- or diminished efficacy-induced) - CTCAE Grade 3 or 4 (clinical effect score D or E) - CTCAE Grade 5 (clinical effect score F)	+ ++	++
Level of evidence supporting the associated clinical effect grade ≥ 3 - One study with level of evidence score ≥ 3 - Two studies with level of evidence score ≥ 3 - Three or more studies with level of evidence score ≥ 3	+ ++ +++	+++
Number needed to genotype (NNG) in the Dutch population to prevent one clinical effect grade ≥ 3 $100 < \text{NNG} \leq 1000$ $10 < \text{NNG} \leq 100$ $\text{NNG} \leq 10$	+ ++ +++	+
PGx information in the Summary of Product Characteristics (SmPC) - At least one genotype/phenotype mentioned OR - Recommendation to genotype OR - At least one genotype/phenotype mentioned as a contra-indication in the corresponding section	+ ++ ++	+
Total Score:	10+	7+
Corresponding Clinical Implication Score:		Essential